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Abbreviations 
5-FC 5-fluorocytosine 
FdUMP 5-fluorodeoxyuridine monophosphate 
5-FU 5-fluorouracil 
ADCC antibody-dependent cellular cytotoxicity 
APC adenomatous polyposis coli 
APC antigen-presenting cell 
APME acute postinfectious measles encephalitis 
BiTE bispecific T-cell engagers 
CD16 cluster of differentiation 16 receptor, Fc receptor 
expressed on NK cells 
CD20 cluster of differentiation 20 receptor, expressed by B-
cell Non-Hodgkin lymphoma  
CD28 cluster of differentiation 28 receptor, costimulatory 
T-cell receptor 
CD46 / MCP membrane cofactor protein, plays a role in host cell 
entrance of measles vaccine virus 
CD56 cluster of differentiation 56, expressed on NK cells 
CD80 / B7.1 cluster of differentiation 80, ligand of CD28 receptor 
CD86 / B7.2 cluster of differentiation 86, ligand of CD28 receptor 
CD107 / LAMP-1 cluster of differentiation 107 / lysosomal-associated 
membrane protein-1, marker of NK cell activity 
CD150 / SLAM cluster of differentiation 150 / signaling lymphocytic 
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activation molecule 
CD152 / CTLA-4 cluster of differentiation 152 / cytotoxic T-
lymphocyte-associated antigen-4 
CD273 / PD-L2 / B7-DC cluster of differentiation 273 / programmed cell death 
2 ligand 
CD274 / PD-L1 / B7-H1 cluster of differentiation 274 / programmed cell death 
1 ligand 
CD279 / PD-1 cluster of differentiation 279 / programmed cell death 
1 receptor 
CEA carcinoembryonic antigen 
CI cell index 
CI confidence interval 
CPE cytopathic effect 
CR complete response 
CRC colorectal carcinoma 
CTL cytotoxic T-lymphocyte 
DAMP danger-associated molecular pattern 
DC dendritic cell 
DLT dose limiting toxicity 
DMEM Dulbecco’s modified Eagle medium 
DMSO dimethylsulfoxide 
dpi days post infection 
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EDTA ethylenediaminetetraacetic acid 
EGFR epidermal growth factor receptor 
E : T ratio effector : target cell ratio 
FACS fluorescence-activated cell sorting 
FAP familial adenomatous polyposis 
FBS / FCS fetal bovine serum / fetal calf serum 
FITC  fluorescein isothiocyanate 
GBM glioblastoma 
GFP green fluorescent protein 
GM-CSF granulocyte-macrophage colony-stimulating factor 
GMP good manufacturing practice 
HCG human chorionic gonadotropin 
HNPCC hereditary non-polyposis colon cancer 
hpi hours post infection 
HSV-1 human herpes simplex virus type 1 
IBD inflammatory bowel disease 
ICD immunogenic cell death 
ICI immune checkpoint inhibitor 
IFIT interferon-induced protein with tetratricopeptide 
repeats 
IFN interferon 
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IgSF immunoglobulin superfamily 
mAb monoclonal antibody 
MCP membrane cofactor protein (also CD46) 
MeV measles vaccine virus 
MHC major histocompatibility complex 
MIBE measles inclusion body encephalitis 
MOI multiplicity of infection 
MSI microsatellite instability 
MSS microsatellite stability 
NCI National Cancer Institute 
NDV Newcastle disease virus 
NIS sodium iodide symporter 
NOD / SCID non-obese diabetic / severe combined 
immunodeficiency 
ORR objective response rate 
OS overall survival 
OV oncolytic virus 
PAMP pathogen-associated molecular pattern 
PBS phosphate buffered saline 
PE phycoerythrin 
PET positron emission tomography 
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PFS progression-free survival 
PR partial response 
PRR pattern recognition receptor 
rpm revolutions per minute 
RECIST Response Evaluation Criteria in Solid Tumors 
rrVSV recombinant replicating vesicular stomatitis virus 
RT room temperature 
SCD super-cytosine deaminase 
SD stable disease 
SD standard deviation 
SEM standard error of the mean 
SLAM signaling lymphocytic activation molecule (also 
CD150) 
SPECT single photon emission computed tomography 
SSPE subacute sclerosing panencephalitis 
TAA tumor-associated antigen 
TCR T-cell receptor 
TH1 cell T helper cell type 1 
TIL tumor-infiltrating lymphocyte 
T-VEC Talimogene laherparepvec 
VEGF vascular endothelial growth factor 
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1. Introduction 
 
1.1. Colorectal cancer as a major health problem 
1.1.1. Epidemiology of colorectal carcinoma 
Colorectal carcinoma (CRC) is considered a major health problem especially in 
industrialized nations. All over the world, this tumor entity depicts the third most 
common diagnosis of cancer (GLOBOCAN 2012, 1.36 million of 14.1 million new 
cancer cases / 9.7 %) and the fourth most common cause for cancer death (694,000 of 
8.2 million deaths / 8.5 %) with a higher incidence in more developed countries (12.1 % 
of new cancer cases in 2012 vs. 7.8 % in less developed countries) (Ferlay et al., 2015). 
Furthermore, referring to data from the US National Cancer Institute between 2012 and 
2014, overall lifetime risk of the diagnosis of CRC is described with 4.3 % of men and 
women (NCI-Webpage, Accessed April 23, 2017). 
In Germany, overall CRC mortality in men decreased by 36.7 % between 1989 and 
2011, in women even by 47.3 % (Ait Ouakrim et al., 2015). In contrast, mortality in all 
34 investigated European countries increased by 6 % in men, whereas it decreased by 
14.7 % in women. Differences between various geographic regions may probably be 
influenced by factors such as access and possibility of screening (especially 
colonoscopy with the possibility to remove early precursor lesions presenting as polyps, 
thus making CRC partly preventable (Simon, 2016)) and of treatment modalities, as 
well as nutritive habits and health-related lifestyle. 
Available access to early screening methods has also a great impact on overall CRC 
mortality, as localized CRC has a 5-year relative survival of 89.9 %, whereas the 
appearance of distant metastases goes along with a 5-year relative survival of only 13.9 
%, citing data from the NCI webpage collected between 2007 and 2013 (NCI-Webpage, 
Accessed April 23, 2017). These data furthermore comprise the necessity of novel 
therapeutic treatment strategies, especially for advanced CRC. 
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A) Cancer incidence and mortality in 2012 in men 
 
B) Cancer incidence and mortality in 2012 in women 
 
Figure 1, A - B: Cancer incidence and mortality in 2012. 
Cancer incidence (blue colored) and mortality (red colored) in (A) men and (B) women in 2012, 
depicting the differences between more and less developed countries. Among different cancer 
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entities, CRC takes rank three in men and rank two in women in regard to incidence in more 
developed countries. Taken of (Ferlay et al., 2015). 
 
1.1.2. Colorectal cancer - an overview of pathology and clinical presentation 
Most colorectal cancers develop in a sporadic, non-hereditary manner, often referring to 
a somatic mutation in the Wnt / β-catenin signaling pathway, namely in the adeno-
matous polyposis coli (APC) tumor suppressor gene (Rowan et al., 2000). 
Hereditary syndrome forms, on the contrary, are rather rare with approximately 5 % of 
CRC (Lung et al., 2015). One of the best known, the familial adenomatous polyposis 
(FAP), is also attributed to a mutation of APC on chromosome 5q21 - q22, but this time 
in the germ line, characterized by up to thousands of adenomatous polyps in 
adolescence (Bodmer et al., 1987; Nakamura et al., 1988; Groden et al., 1991). Another 
hereditary form of CRC displays Lynch syndrome, an entity of hereditary non-polyposis 
colon cancer (HNPCC) with germ line mutation leading to DNA mismatch repair 
deficiency, followed by an enormous rate of mutations. This inheritable defective DNA 
repair mechanism is also associated with numerous extracolonic cancers, most of all 
endometrial and ovarian (Carethers and Stoffel, 2015; Lung et al., 2015). 
Prolonged inflammation as a key factor in carcinogenesis likewise concerns forms of 
CRC, for example in patients with diagnosed inflammatory bowel disease (IBD), such 
as ulcerative colitis or Crohn’s disease (Lasry et al., 2016). Furthermore, this goes along 
with the finding that proinflammatory cytokines are able to increase Wnt signaling 
pathway activity (Ostaff et al., 2013). Emphasizing these links between inflammation 
and CRC, a further factor of carcinogenesis has to be taken into account: microbiota. To 
give only one example, investigations could show that the toxin of Bacteroides fragilis 
was able to increase transcription of β-catenin-regulated oncogenes (Sears, 2009; Saleh 
and Trinchieri, 2011). 
Apart from discussed pathogenesis factors of hereditary impact, family history of CRC 
and inflammation, also advanced age, black race, obesity, diabetes mellitus and 
smoking as well as alcohol consumption have been revealed as risk factors for CRC 
development (Cai et al., 2014; Oluyemi et al., 2014). As for advanced age, about 90 % 
of CRC occur beyond age of 50 (Herold, 2015). 
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Clinical presentation of CRC does not go along with reliable early symptoms, but blood 
admixture in stool or sudden changes in dejection habits can belong to the clinical 
pattern. 
Histopathological definition of a malignant polyp includes invasion of muscularis 
mucosae, hence being referred to as pT1 and being capable of metastasis (Engstrom et 
al., 2009).  
The way of metastasis follows mainly the portal vein, turning the liver and, secondly, 
the lung into most preferred regions of early tumor filiae. For metachronous liver 
metastases, cumulative 10-year incidences after first diagnosis of CRC are ranked at 
about 6 % for stage I and up to 30 % at stage III (Landreau et al., 2015). 
 
1.1.3. Existing therapeutic possibilities and problems in treatment of colorectal 
cancer 
Surgery represents the therapy option with greatest significance in treatment of CRC in 
both primary tumor and metastases in liver or lung, if complete tumor resection is 
possible. With the total mesocolic or mesorectal excision and the ablation of lymph 
nodes as well as infiltrated neighboring organs, a maximal local radicalness is supported 
(Herold, 2015). Although 70 - 80 % of patients with CRC diagnosis can be resected in 
sano (R0), 40 - 50 % suffer recurrence or later metastases (Gustavsson et al., 2015). 
Neoadjuvant or adjuvant (radio-) chemotherapy is used to treat higher UICC stages, 
including conventional chemotherapy with an oxaliplatin- or fluoropyrimidine-based 
regimen. For colon cancer, adjuvant chemotherapy is referred to as gold standard for 
stage III or higher in order to eliminate possible micrometastases and to improve 
progression-free survival (PFS) as well as overall survival (OS) (Lombardi et al., 2010; 
Gustavsson et al., 2015). 
The basis of the existing chemotherapy protocols represents 5-fluorouracil (5-FU), since 
its converted form 5-fluorodeoxyuridine monophosphate (FdUMP) appeared to be a 
potent inhibitor of thymidylate synthetase as a suicide substrate (Danenberg, 1977). 
Thymidine-containing desoxyribonucleotides result from methylation of uracil-
containing desoxyribonucleotides through thymidylate synthetase, thus being a key step 
of nucleic acid synthesis, which becomes blocked by 5-FU. Furthermore, incorporation 
of 5-FU into RNA as well as DNA is another mechanism of 5-FU-induced cytotoxicity 
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(Gill et al., 2003). Soon, folinic acid (leucovorin) was added to the treatment regimen, 
resulting in a prolonged survival, increased tumor response rates as well as improved 
PFS (Poon et al., 1989).  
Together with the topoisomerase I inhibitor irinotecan, oxaliplatin and the oral 5-FU 
prodrug capecitabine, the existing treatment regimens were compiled. 
As the era of monoclonal antibodies was introduced, bevacizumab, targeted against 
vascular endothelial growth factor (VEGF), and cetuximab / panitumumab, targeted 
against the epidermal growth factor receptor (EGFR) in patients with K-RAS wildtype 
(wt), replenished the spectrum of possible chemotherapeutics in CRC treatment. But 
yet, the median OS achieved in combination studies for metastatic disease in the last 30 
years did not rise above 23.9 months (Gustavsson et al., 2015), thus making the research 
for new therapeutical approaches inevitable. 
 
1.2. Virotherapy as an anti-cancer treatment approach 
1.2.1. Principles of virotherapy - how an infectious virus becomes anti-cancer therapy 
The idea behind virotherapy refers to the principle of tumor-specific oncolysis, 
therefore applying a virus with the hallmark of infecting tumor cells for replication and 
lysis afterwards, but sparing the surrounding healthy tissue. With the tumor cell lysis, 
viral progenies are released, which further infect neighboring tumor cells, thus 
representing a self-amplifying anti-cancer agent. Besides, concerning safety issues, the 
oncolytic virus (OV) should possess the trait of genetic stability as well as limited 
human pathogenicity, conceivably with well-known antiviral treatment available, also 
taking attenuated vaccine viruses or animal-pathogenic viruses into account (Kelly, 
2007). Finally, a hurdle in introducing new virotherapeutics consists in production of 
needed virus doses in terms of good manufacturing practice (GMP) guidelines (Thorne 
et al., 2005).  
Since the process of oncolysis leads to release of tumor-associated antigens (TAAs), 
thus setting an immunological stimulus, the direct tumor damage is completed by 
activating the host immune system against cancer, evading the tumorous immune 
escape mechanisms and thereby portraying virotherapy in an immunotherapeutical 
context (Naik et al., 2011; Russell et al., 2012). To put it into a nutshell, viral oncolysis 
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induces both innate immunity and adaptive anti-tumor immune response via tumor-
specific T-cell priming (Melcher et al., 2011; Naik et al., 2011; Turnbull S, 2015). The 
highly immunogenic cell death (ICD) following viral lysis shapes the tumor 
microenvironment towards a pro-inflammatory background, for example through 
release of pathogen-associated molecular patterns (PAMPs) or danger-associated 
molecular patterns (DAMPs): PAMPs display conserved microbial molecules identified 
via pattern recognition receptors (PRRs), whereas DAMPs lead to activation of innate 
immune cells such as dendritic cells (DCs) or tumor macrophages, which further 
arrange adaptive anti-tumor immune responses (Prestwich et al., 2009; Donnelly et al., 
2013; Woller N, 2014; Hardcastle et al., 2016; Marchini et al., 2016). 
 
Figure 2: Virotherapy as highly immunogenic stimulus 
OV-induced oncolysis functions as immunological impulse towards an innate as well as 
adaptive anti-tumor immune response. With the release of so-called pathogen-associated 
molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), antigen-
presenting cells (APC) such as dendritic cells (DC) are stimulated to mediate the 
immunological interplay against the foreign tumor neoepitopes. Figure from (Woller N, 2014). 
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Another mechanism of OV-induced tumor mass reduction involves strategies to impair 
tumor sustentative blood supply by targeting tumor endothelial cells (Breitbach et al., 
2013). Moreover, OVs were even found to aim at cancer stem cells, which are often 
resistant to conservative radio- or chemotherapy and play a crucial role in tumor relapse 
(Smith et al., 2014; Marchini et al., 2016). 
The leading characteristic of a candidate for virotherapy is certainly specificity in 
infection and replication behavior in terms of tumor cell tropism. Actually, several 
specifics of tumor cells make them more accessible for virus entrance and replication in 
comparison to related healthy tissue. To set an example, tumorigenesis mainly relies on 
the principles of avoiding apoptosis and of supplying autonomous growth, whereas a 
response to viral infection rather implements the opposite: apoptosis and inhibition of 
production of viral proteins via stop of translation (Russell et al., 2012). Namely, 
mutations in antiviral response pathways such as the interferon α / β	response make the 
tumor cell incapable of defending against viral infection. Nevertheless, these mutations 
are common: As interferon simultaneously impedes tumor growth, interferon pathway 
deficiency turns out to be advantageous in carcinogenesis (Stojdl et al., 2000; Russell 
and Peng, 2009). 
 
Figure 3: Principles of tumor-specific viral oncolysis 
Tumor cells are preferentially accessible for viral infection, as important antiviral pathways 
such as the interferon (IFN) pathway appear to be impaired in favor of unhindered tumor 
growth. Figure modified after (Liu T.C., 2007). 
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Other ways of targeting virus to cancer cells imply the usage of OVs dependent on 
tumor-specific surface receptors and proteases for host cell fusion and entry, or involve 
the exploitation of distinct specificities of replication and transcription in tumor cells 
(Cattaneo et al., 2008). 
A problem still to face in the field of virotherapy depicts the immunological clearance 
of systemically applied OV, especially of viruses also used for vaccination or with 
broad immunity-creating propagation (Fisher, 2006; Russell and Peng, 2009; Msaouel 
et al., 2013; Marchini et al., 2016). To elude such an early immunological clearance of 
OV by neutralizing antibodies in the bloodstream, several approaches were 
implemented in preclinical testing: combination of OVs with immunosuppressive drugs 
such as cyclophosphamide (Msaouel et al., 2013; Peng et al., 2013), protective coating 
of the virus particle (Fisher et al., 2001) or usage of so-called cell carriers (Iankov et al., 
2007). It will be the challenge to get the balance between optimal OV-induced anti-
tumor immune responses on the one hand and effective viral spread on the other hand. 
 
1.2.2. History of virotherapy - from historical approaches to new generations of 
genetically engineered oncolytic viruses 
In the early 20th century, the finding of viral oncolytic potential shortly followed the 
discovery of virus existence, when doctors witnessed cancer regression under naturally 
acquired viral infections (Kelly, 2007; Russell and Peng, 2009). But not until more than 
half a century had passed, clinical observances heralded the modern era of virotherapy 
in the 1970s and 1980s: In several cases, measles disease obtained shrinking of 
prominent Burkitt’s lymphoma tumors, shortly after the typical measles exanthema was 
noticed (Bluming, 1971; Taqi et al., 1981). Moreover, several cases of tumor regression 
in patients with Hodgkin’s disease (Greentree, 1983; Schattner, 1984) or chronic 
lymphatic leukemia (Hansen and Libnoch, 1978) were described after vaccination 
against measles or smallpox. Although the exact mechanisms of tumor-specific 
oncolysis were not fully understood, the immune-enhancing role of viral infection was 
assumed to be an important part of the resulting therapeutic effect, also considering the 
immunocompromised state accompanying those hematological tumor entities (Kelly, 
2007). As early as 1973, Minton et al. used killed mumps virus for an immune 
stimulation 
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treatment strategies such as surgery and chemotherapy, but still, clinical benefit was not 
of long duration (Minton, 1973; Kelly, 2007). 
Furthermore, several animal viruses were tested as an oncolytic therapeutic with 
controllable virulence: In contrast to many human pathogenic viruses, which are wide-
spread as natural infections or part of vaccination programs, animal viruses implicate 
the advantage of not being exposed to immunological clearance by preexisting anti-
bodies (Kelly, 2007). 
When successful cultivation of virus in laboratories, establishment of human cancer 
models in rodents and, finally, reverse genetics entered the stage of clinical basic 
research, virotherapy experienced a new boom (Kelly, 2007; Cattaneo et al., 2008; 
Russell and Peng, 2009). With the partly insufficient tumor tropism, the problem of 
early OV clearance by the host immune system or the lack of oncolysis efficacy, the era 
of viral genome manipulation in the late 20th century implied an enormous progress in 
establishing virotherapy in the field of oncology. But as a matter of fact, first attempts 
to improve efficacy of virus-mediated oncolysis had already been made before, for 
example as Moore and colleagues discovered that Russian Far East encephalitis virus 
provided better results in oncolysis of sarcoma after having been propagated in sarcoma 
cells beforehand, thereby enabling an adaption of viral replication to the host cell 
(Moore, 1952; Kelly, 2007).  
Utilizing the new options in genetic engineering, experiments of retargeting OVs to 
surface molecules expressed by cancer cells succeeded, with CD20 (Non-Hodgkin 
lymphoma) (Bucheit et al., 2003) or carcinoembryonic antigen (CEA) (Hammond et al., 
2001) as exemplary targets for creating a more specific tumor tropism. Other 
approaches of viral genome manipulation made non-invasive monitoring of viral 
spread- and elimination-kinetics possible, for example via insertion of marker genes 
such as CEA or the β-unit of human chorionic gonadotropin (β-HCG), whose serum 
levels not only reflected viral replication kinetics, but also correlated with the 
therapeutic outcome in animal models (Peng et al., 2002a). 
With regard to the field of radiovirotherapy, treatment with a measles vaccine virus 
(MeV) expressing the sodium iodide symporter (NIS), which can be found on thyroid 
follicular cells for iodide transport into the cell, was combined either with the 
application of I-123, or with the β-emitter	I-131. Thereby, monitoring of viral growth 
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kinetics via positron emission tomography (PET) or single photon emission computed 
tomography (SPECT) in the former, as well as an additive therapeutic option in the 
latter case could	be	realized	(Dingli et al., 2004).  
Genetic engineering was also used in attempt to increase anti-tumor immunostimulatory 
effects, for example enabling herpes virus (T-Vec) or vaccinia virus (JX-594) to express 
the granulocyte-macrophage colony-stimulating factor (GM-CSF) (Park et al., 2008; 
Kaufman et al., 2010). Finally, suicide-gene functions were exploited to convert 
systemically administered, harmless prodrugs into highly effective, local chemo-
therapies: By directly delivering necessary transforming enzymes via OV-vectors to the 
tumor location, preexisting resistances against virotherapy were successfully overcome 
(Graepler F., 2005; Lampe J, 2013; Lange S, 2013; Noll M., 2013; Yurttas C, 2014). 
To put it into a nutshell, possibilities of genetic engineering induced metamorphosis of 
virotherapy into a multifunctional instrument in cancer treatment. 
 
1.2.3. Oncolytic virus in clinical usage - from bench to bedside 
With the introduction of the first FDA- and EMA-approved virotherapeutic on the 
market in 2015, Imlygic® (Talimogene laherparepvec, Amgen, also shortened as T-VEC 
and developed as OncoVEXGM-CSF), a great hurdle was overcome in clinical 
development of virotherapy as an anti-cancer treatment. Approval of the GM-CSF 
expressing human herpes simplex virus HSV-1 for treatment of unresectable stage III / 
IV melanoma was given, after efficacy and, simultaneously, safety as well as feasibility 
of application were proven in a first phase III clinical trial with prolongation of overall 
survival (OS) from 18.9 months (GM-CSF only) to 23.3 months (T-VEC) (P = 0.051) 
(Andtbacka, 2015). Engineered to sustain major histocompatibility complex I (MHC I) 
presentation, to produce GM-CSF and to achieve effective, tumor specific viral 
replication and limited neuropathogenicity at the same time, T-VEC belongs to the third 
generation of OVs, genetically armed for better anti-tumor efficacy (Liu T.C., 2007; 
Andtbacka, 2015; Johnson et al., 2015). 
Without this possibility of sophisticated viral gene modification in the middle of the last 
century, early clinical trials had been executed with wildtype viruses, domesticated 
through passage in cell culture, such as West Nile virus, adenovirus, mumps or vaccinia 
virus (Liu T.C., 2007). 
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Currently, along with herpes simplex virus, numerous virotherapeutics are under 
clinical development, for example MeV, focused on non-invasively trackable MeV-
CEA and MeV-NIS (described in 1.2.2). Namely, a phase I trial of intratumoral or 
resection cavity application of MeV-CEA in glioblastoma multiforme patients 
investigated safety issues, with no dose limiting toxicities (DLTs) reported so far 
(ClinicalTrials.gov identifier NCT00390299) (Msaouel et al., 2009). In another phase I 
trial, MeV-NIS and MeV-CEA are tested for therapeutic efficacy against ovarian 
cancer, also exploring safety and toxicity in a dose escalation study, as well as shedding 
of replication-capable virus (NCT00408590) (Galanis et al., 2010). Along with 
predisposition to mutate or revert to wildtype, environmental shedding, for example in 
saliva, urine or blood, has to be particularly attributed in clinical trials with virothera-
peutics, which descend from originally pathogenic strains (Buijs et al., 2015). 
Addressing the tumor entity of treatment-refractory CRC, a first virotherapeutic phase 
Ib dose-finding trial was conducted with i.v. vaccinia virus Pexa-Vec, leading to a stable 
disease (SD) in 67 % of patients (Park et al., 2015). Furthermore, infusions of herpes 
simplex virus NV1020 or oncolytic adenovirus dl1520 (Onyx-015) into the hepatic 
artery were tested for CRC liver metastasis in phase I / II studies, resulting in acceptable 
toxicity profiles (Reid et al., 2002; Geevarghese et al., 2010). 
To overcome tumor-immanent resistances against viral oncolysis, researchers and 
clinicians now head for combination therapies with conventional chemotherapy, radio-
therapy, immunotherapy or targeted therapy. To give an example, squamous cell cancer 
of the head and neck is treated in a phase I/ II trial with T-VEC together with cisplatin 
and radiotherapy, resulting in 82.3 % of patients showing response according to 
RECIST criteria (Response Evaluation Criteria in Solid Tumors) (Harrington et al., 
2010). 
Multimodal immunovirotherapeutic treatment (for details, see 1.5), including immune 
checkpoint blockade, is evaluated in clinical phase Ib/II trials (T-VEC and ipilimumab / 
Yervoy®, Bristol-Myers Squibb, in patients with advanced melanoma, NCT01740297), 
as well as phase Ib/III trials (T-VEC and pembrolizumab / Keytruda®, MSD, also for 
treatment of advanced melanoma, NCT02263508). First results for T-VEC and 
ipilimumab prove tolerable safety without appearing DLTs and a 50 % objective 
response rate (ORR, 95 % CI, 26.0 to 74.0), including four patients (22 %) with 
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complete response (CR) (Puzanov et al., 2016). With regard to MeV virotherapy, a 
phase I study combining MeV-NIS with the immune checkpoint inhibitor (ICI) 
nivolumab (Opdivo®, Bristol-Myers Squibb) will start recruiting patients with recurrent 
non-small cell lung cancer in 2017 (NCT02919449). 
One of the latest successes in the field of immunovirotherapy was the treatment of 
advanced melanoma with Talimogene laherparepvec and pembrolizumab in a phase Ib 
clinical trial (NCT02263508) (Ribas et al., 2017), resulting in no apparent increase in 
toxicity compared to the respective monotherapies. In the rather small patient cohort of 
21, an ORR of 62 % was found, including CRs in 33 % of patients (both referring to 
immune-related response criteria). An ongoing phase III study allocates patients with 
advanced melanoma in a Talimogene laherparepvec plus pembrolizumab or a placebo 
plus pembrolizumab arm to further investigate OS as well as PFS (NCT02263508). 
To summarize, virotherapy has made a fine step forward towards proving its worth in 
clinical oncology, considering numerous clinical trials and the approval of Imlygic®. 
 
1.3. Measles virus - boon or bane in modern medicine? 
1.3.1. Morphology and classification of measles virus 
Measles virus, member of the family Paramyxoviridae, genus Morbillivirus, belongs to 
the enveloped viruses, containing a 16 kb negative strand genomic RNA coated with a 
nucleocapsid. The virion has a size of about 100 to 300 nm and is configured out of six 
structural proteins (Duke and Mgone, 2003; Knipe, 2013). 
Two glycoproteins, viral transmembrane hemagglutinin (H) and the fusion protein (F), 
were found responsible for receptor targeting (H) and viral entrance via membrane 
fusion (F) in Paramyxoviridae such as measles (Navaratnarajah et al., 2011). Measles 
wildtype virus possesses the ability to bind to the signaling lymphocytic activation 
molecule (SLAM or CD150) on B- and T-lymphocytes (Tatsuo et al., 2000) or to 
nectin-4 on human airway epithelium (Mühlebach M. D., 2011) for cell entrance, but 
measles vaccine strains such as Edmonston strain are also able to target the so-called 
membrane cofactor protein (MCP or CD46), which plays a role in regulation of the 
complement system. Interestingly, CD46 is expressed ubiquitously on nucleated cells 
(Dorig et al., 1993) and also on human tumor cells, here even in a higher degree 
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(Russell and Peng, 2009), which makes measles vaccine virus (MeV) suitable as a viro-
therapeutic. 
Other structural proteins are the matrix protein (M), nucleocapsid protein (N), 
phosphoprotein (P) and large polymerase proteins (L). The basic matrix protein (M) is 
part of the virion’s envelope, together with H and F. The nucleocapsid protein (N) is the 
protein transcribed first as well as most frequently, building the helical ribonucleocapsid 
together with the RNA genome. A component of replicase complex represents the large 
protein (L) with polymerase function, which is also part of the nucleocapsid and 
associated with the phosphoprotein (P), being a polymerase cofactor.  
The wildtype virus phosphoprotein transcription unit also codes for the proteins C and 
V, which, together with P, circumvent the translocation of STAT to the nucleus as well 
as STAT1 and STAT2 phosphorylation, thus counteracting the antiviral interferon 
response and enabling viral spread more efficiently (Cattaneo et al., 2008; Russell and 
Peng, 2009). Interestingly, an oncolytic MeV, genetically engineered to code for the 
wildtype P gene, was able to circumvent innate tumor cell immunity via suppression of 
the IFN pathway (Haralambieva et al., 2007). 
 
Figure 4, a - b: Schematic structure of the measles virus particle (a) and its respective 
genome (b) 
The enveloped measles virus particle (a) consists of six structural proteins. The matrix proteins 
(M) encompass the so-called ribonucleoprotein complex, comprising the nucleoprotein (N), 
which coats the negative strand genomic RNA, the RNA-dependent RNA polymerase called 
large protein (L) and its cofactor, the phosphoprotein (P). Hemagglutinin (H) and fusion 
protein (F) are responsible for receptor targeting as well as viral invasion into the host cell via 
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membrane fusion. The measles viral genome (b) codes for the six viral proteins and implies a 
transcriptional gradient from the N protein to the L protein with a decreasing amount of 
resulting protein products. The proteins C and V are alternative products of P and play an 
important role in antagonizing antiviral interferon responses. Figure from (Aref et al., 2016). 
 
Genetically engineered measles vaccine virus used in the field of virotherapy often 
encodes for further proteins, for example for the green fluorescent protein (GFP) to 
monitor successful infection, or for the prodrug-converting super-cytosine deaminase 
(SCD), which implements additional therapeutic effects in combination with the 
substrate and prodrug 5-fluorocytosine. Thereby, the transcriptional gradient from the N 
to the L protein implies that a gene position upstream of the region coding for the N 
protein results in maximal expression of the wanted protein product (see Fig. 5) (Lampe 
J, 2013; Hutzen et al., 2015). 
 
Figure 5: Schematic structure of the genetically engineered measles virus genome 
Genetically engineering of measles vaccine virus in the field of virotherapy implicates new 
possibilities of enhanced therapeutic effects or monitoring of virus spread. Based on 
recombinant technologies, marker genes such as the green fluorescent protein (GFP) or 
therapeutic genes such as the super cytosine deaminase gene (SCD) can be inserted into the 
viral backbone. 
 
The pathognomonic cytopathic effect (CPE) of measles infection depicts the formation 
of multinucleated syncytia after fusion of cells, also observable in vitro (Aref et al., 
2016). Furthermore, syncytia formation was found to be dependent on CD46 
expression, thereby leading to increased cell fusion in tumor cells, as they often 
overexpress CD46 (Anderson et al., 2004). Other cytopathic effects are altered cell 
shape as well as inclusion bodies (Nakai and Imagawa, 1969). 
With only one serotype existent, a monovalent vaccine is sufficient to protect against 
measles disease, but still, eight different classes (A - H) as well as several genotypes are 
distinguished, taking the gene sequences coding for M and H into account (Duke and 
Mgone, 2003). 
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1.3.2. Measles virus as an infectious pathogen - epidemiology and clinical 
appearance 
As a highly contagious illness, measles are a major health problem especially in 
developing countries, where vaccination is not available to everyone and where 
particularly children die as a consequence of severe measles infection. But also in 
industrialized nations with persisting vaccination gaps in the population, measles 
outbreaks are still on the agenda, listing 2.464 cases of measles in 2015 in Germany, 
with largest incidences in one-year-old and younger children (Robert-Koch-Institut, 
2016). Measles infection is a droplet infection entering via respiratory tract and casually 
via conjunctivae, while dissemination takes place via reticuloendothelial system (Duke 
and Mgone, 2003). After an incubation time of 10 - 12 days, prodromal symptoms such 
as rhinitis, conjunctivitis, fever, cough or measles enanthema (the pathognomonic 
Koplik spots) and, a few days later, exanthema evolve. Pneumonia turned out to be the 
most common fatal complication, accounting for 56 - 86 % of measles-related deaths, 
also often due to bacterial or viral superinfection (Duke and Mgone, 2003; Herold, 
2015). Acute postinfectious measles encephalitis (APME), measles inclusion body 
encephalitis (MIBE) and subacute sclerosing panencephalitis (SSPE) represent 
complications concerning the central nervous system in the context of measles 
infection, but are fortunately rather rare (Duke and Mgone, 2003). 
Interestingly, on the one hand, measles infection is associated with an induced 
immunosuppression with lymphopenia, opening the floodgates to opportunistic 
infections, whereas on the other hand, the resulting anti-measles immune response leads 
to lifelong immunity (de Vries and de Swart, 2014). 
 
1.3.3. Measles vaccine virus as a virotherapeutic agent 
With the already mentioned advantageous characteristic of MeV being able to target 
CD46, which is often overexpressed in tumor cells, and with the acceptable low toxicity 
as an attenuated vaccine strain (Msaouel et al., 2012), MeV seems to be an outstanding 
candidate for the development of a virotherapeutic. Moreover, MeV is able to harbor 
transgenes of large size, still with proven genetic stability (Buijs et al., 2015). 
Thus, measles OV already took part in numerous preclinical testing, resulting in 
successful virotherapy of various tumor entities such as melanoma (Donnelly et al., 
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2013; Kaufmann et al., 2013), lymphoma (Grote et al., 2001; Heinzerling et al., 2005; 
Kunzi et al., 2006), myeloma (Peng et al., 2001; Liu et al., 2010), hepatocellular 
carcinoma and other tumors of the liver (Blechacz, 2006; Zimmermann et al., 2009), 
glioblastoma (Phuong et al., 2003), ovarian cancer (Peng et al., 2002b; Hasegawa et al., 
2006) or pancreatic cancer (Penheiter et al., 2010), just to give some examples. 
Nevertheless, the usage of oncolytic MeV, which mostly descends from the attenuated 
vaccine Edmonston strain, brings along several problems to deal with. First of all, the 
high rate of vaccination in our population results in the problem of immunological 
clearance of systemically applied measles virus - one of the main obstacles of 
implementation of MeV-based virotherapy into clinical practice (Russell and Peng, 
2009). Yet, the anti-measles vaccination also displays a certain protection against 
unintended spread after application of MeV as virotherapeutic agent. Moreover, along 
with the clinical vaccination experience over the last decades, this virus can be referred 
to as fairly safe for usage in humans (Msaouel et al., 2009). 
Facing the clinical introduction of MeV, the problem of appropriate model systems in 
animals emerged. As mice do express neither CD46 nor SLAM (Msaouel et al., 2009), 
transgenic CD46 expressing mice had to be developed for safety evaluation (Mrkic et 
al., 1998; Kemper et al., 2001). By retargeting MeV to CD20, a CD20 expressing 
murine B16 melanoma model was successfully introduced, implying the advantage of 
an immunocompetent murine model, which was an inevitable step for testing MeV in 
the background of cancer immunotherapy (Engeland CE, 2014). Furthermore, 
preclinical toxicity testing was performed in non-human primates such as rhesus 
macaques (Msaouel et al., 2009). 
With the replication-trackable virotherapeutics MeV-CEA and MeV-NIS (as described 
in 1.2.2), representatives of the genus Morbillivirus finally entered the stage of clinical 
phase I and II trials (for details, see 1.2.3). 
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1.4. Immunotherapy as an anti-cancer treatment approach 
1.4.1. Principles of immunotherapy - how to activate the body’s defence against 
cancer 
Gene mutations and dysfunctional epigenetics are distinctive hallmarks of carcino-
genesis, resulting in expression of new proteins, which are foreign to our immuno-
logical self. With those potential epitopes for activation of an anti-cancer immune 
response, a tumor has to develop several immune escape mechanisms to circumvent an 
attack by the host’s immune system. ‘Immunoediting’ and ‘immunosubversion’ are two 
main strategies, implying selection of the least immunogenic tumor subclones and, on 
the other hand, following active prevention of immunological clearance by involving 
cellular and humoral manipulation of tumor microenvironment and tumor-distinct 
mechanisms, such as downregulation of MHC or expression of so-called immune 
checkpoint ligands (Zitvogel et al., 2006). The cellular components of cancer immune 
escape contain regulatory T-cells as well as myeloid-derived suppressor cells, while 
interleukin 6, interleukin 10, vascular endothelial growth factor or transforming growth 
factorβare part of the soluble elements in abrogating anti-tumor immune responses 
(Topalian et al., 2011). 
In the last decades, cancer research turned its attention to the role of immune 
checkpoints, which represent costimulatory or inhibitory receptors expressed on several 
immune effector cells. Together with their corresponding ligands, they were found to be 
responsible for modulating immune responses. 
For stimulation of naïve T-cells through a particular epitope, descending from a mutated 
cancer cell, two signals are necessary. First of all, the processed host-foreign antigen is 
presented via MHC class I to the T-cell receptor (TCR), which is done by DCs, acting 
as professional APCs. But without costimulatory signals, the T-cell would become 
anergic, hence not reactive (Esensten et al., 2016). The CD28 receptor on naïve CD4+ 
and CD8+ T-cells provides such a coregulatory, antigen-independent signal in case of 
stimulation by APCs, which express the ligands B7.1 (CD80) and B7.2 (CD86) (Chen 
and Flies, 2013; Zamarin D, 2015). Activation of CD28, member of immunoglobulin 
superfamily (IgSF), finally results in T-cell survival, proliferation and differentiation 
(Esensten et al., 2016). By contrast, inhibitory receptors, so-called immune checkpoint 
receptors such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4, also referred 
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to as CD152), compete against CD28, inhibiting IL-2 release and T-cell activity and 
furthermore possessing higher affinity for both CD28 ligands (Leach et al., 1996; 
Waldmann, 2003). 
Physiologically, the mechanism of APCs expressing those immune checkpoint ligands 
avoids autoimmune incidents and ensures immunological homeostasis, while cancer 
cells abrogate this mechanism for immune evasion. This is emphasized in the fact that 
Ctla-4-knockout mice suffer from severe systemic immune hyperactivation, not being 
able to keep T-cell response against self-antigens under control (Waterhouse et al., 
1995).  
In contrast to this, as already described as a mechanism of ‘immunosubversion’, tumor 
cells express immune checkpoint ligands to impede anti-tumor immune response 
(Zitvogel et al., 2006). These are the requirements for the grand entrance of therapeutic 
antibodies called immune checkpoint inhibitors (ICI), targeting receptors or ligands of 
immune checkpoint pathways to abrogate tumor immune escape or, in other words, 
create an anti-tumor immunity (Leach et al., 1996). 
Whereas CTLA-4 represents an immune checkpoint pathway which modulates initial T-
cell activation, some other immune checkpoint receptors such as programmed cell death 
1 receptor (PD-1 or CD279) and its ligands PD-L1 (also known as B7-H1 or CD274) 
and PD-L2 (also known as B7-DC or CD273) play an outstanding role in the regulation 
of ongoing T-cell immune responses (Topalian et al., 2011; Bauzon M, 2014; Postow et 
al., 2015). In contrast to CTLA-4, PD-1 can also be found on non-T-lymphocytic cells 
such as NK cells, B-cells, activated monocytes or DCs (Keir et al., 2008). As main 
ligand of PD-1 on solid tumors (Bauzon M, 2014), PD-L1 is found to be overexpressed 
in many human carcinomas, whereas healthy tissues do not express PD-L1 (Dong H., 
2002). Receptor / ligand interaction downregulates T-cell proliferation and cytokine 
production, and thus counteracts anti-tumor immune response. Moreover, IFN type I 
and IFN type II signaling both work as possible inductors of PD-L1 expression (Keir et 
al., 2008). 
High degrees of PD-L1 expression in the tumor microenvironment, especially on tumor-
infiltrating immune cells, proved to be favorable for developing responses on ICI 
therapy influencing PD-1 / PD-L1 pathway (Topalian et al., 2012; Taube et al., 2014). 
In a broader sense, a preexisting anti-tumor immune response such as tumor infiltration 
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with tumor-infiltrating lymphocytes (TILs) is in favor of ICI therapy success, as in this 
case, immune checkpoint blockade is able to counteract ensuing processes of tumor 
immune escape (Herbst et al., 2014; Tumeh et al., 2014). It thus seems to be the 
challenge to combine immunotherapeutics in a way that induces and improves anti-
tumor immune responses, even in poorly immunogenic cancer entities. 
 
1.4.2. Immune checkpoint inhibitors entering the stage of clinical trials as anti-cancer 
drugs 
With the anti-CD20 antibody rituximab, the first monoclonal antibody (mAb) was 
approved as anti-cancer drug in the 1990s, followed by numerous other mAbs against 
specific tumor-related antigens (Waldmann, 2003). Thus, the era of passive 
immunotherapy was initiated with a focus on targeted tumor therapy. 
Along with immune checkpoint blockade and anti-tumor-targeted mAbs, cancer 
vaccines and adoptive cell transfer also belong to the today’s spectrum of immuno-
therapy. But until the first ICI, the CTLA-4-targeted antibody ipilimumab (Yervoy®, 
Bristol-Myers Squibb), was FDA-approved for grade 3 and 4 melanoma in 2011, active 
immunotherapy was quite underestimated in clinical practice. 
Pembrolizumab (Keytruda®, MSD) was the first immune checkpoint targeted against 
PD-1 to be approved by FDA in 2014, and several others such as nivolumab (Opdivo®, 
Bristol-Myers Squibb, 2014) against PD-1 or atezolizumab (Tecentriq®, Roche, 2016) 
against PD-L1 followed, partly in fast-track approval procedure (Martin-Liberal et al., 
2017). 
MDX-1106, later nivolumab, which is now approved for unresectable or metastatic 
melanoma (2014), non-small cell lung cancer, renal cell carcinoma (both 2015), 
Hodgkin lymphoma and squamous-cell carcinoma of the head and neck (both 2016), 
was one of the first anti-PD-1 antibodies to enter phase I clinical trials (Martin-Liberal 
et al., 2017). Primarily safety and toxicity issues had to be examined: In this regard, 
good tolerability without any DLTs after a single dose could be proven (Brahmer et al., 
2010). For anti-tumor efficacy, this first trial showed several tumor regressions, along 
with one complete response (CR) in a CRC patient and two partial responses (PR) in 
melanoma and renal cell cancer, thus stating a therapeutic chance even for carcinomas 
considered to be rather non-immunogenic such as CRC (Brahmer et al., 2010). 
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Clinical trials with nivolumab continued up to phase III, for example in patients 
suffering from advanced melanoma as a second-line therapy after pretreatment with 
ipilimumab and, if BRAF mutation diagnosed, BRAF inhibitors, resulting in an 
improvement of objective responses from 10.6 % in the group receiving chemotherapy 
of investigator’s choice to 31.7 % in nivolumab group (Weber et al., 2015). 
With atezolizumab, FDA-approved since 2016 for second-line treatment of urothelial 
cancer after platinum-based chemotherapy (Markham, 2016), a representative of ICIs 
targeting PD-L1 was tested in several clinical trials, for example against cancer of the 
lung (Fehrenbacher et al., 2016) or against metastatic renal cell carcinoma (McDermott 
et al., 2016). In a phase II clinical trial of atezolizumab against urothelial carcinoma 
(NCT02108652), Rosenberg et al. described an ORR of 26 % in patients with ≥ 5 % of 
immune cells in the tumor microenvironment expressing PD-L1 in comparison to an 
ORR of 15 % in the whole study group irrespective of PD-L1 expression. As a 
consequence of those results, PD-L1 expression was given an important role in 
prediction of response to immune checkpoint blockade in urothelial carcinoma patients 
(Rosenberg et al., 2016). Moreover, it is discussed to supplement examination of PD-L1 
expression as sole biomarker with the investigation of preexisting T-cells specific for 
tumorous antigens to make predictions about patient-specific response to inhibition of 
PD-1 / PD-L1 signaling (Shin and Ribas, 2015). To summarize the clinical revolution of 
ICI in cancer immunotherapy, ICI not only became part of the everyday business of 
oncologists, but also progressed to the stage of personalized medicine. 
 
1.4.3. Immunotherapy and colorectal cancer - a way of treatment worthy to go? 
The role of immunotherapy in the treatment of CRC is quite controversial, as two 
different entities have to be differentiated: microsatellite stable (MSS) tumors and, on 
the other hand, CRC with defects in genes coding for DNA mismatch repair, which 
leads to an enormous mutational load and the phenomenon of microsatellite instability 
(MSI) (Boland and Goel, 2010). As those mutations result in numerous proteins foreign 
to our immunological self, thereby potentially serving as epitopes for T-cell activation, 
the consideration has to be why such highly immunogenic tumors can still grow and 
metastasize. This is even underlined with the observation of active CD8+ cytotoxic T-
lymphocytes (CTL) and T helper cells type 1 (TH1 cells) infiltrating the tumor micro-
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environment (Llosa et al., 2015). Apart from that, it is generally accepted that the 
degree of T-cell infiltration of CRC is of high prognostic as well as predictive 
relevance, emphasizing the outstanding role of interplay between tumor and immune 
system (Galon et al., 2006; Jager et al., 2016). 
The fact that immune checkpoint receptors and ligands such as PD-1 and PD-L1 are 
upregulated to a great extent in MSI colorectal tumors does not only explain the 
mechanism of immune escape, but also depicts an interesting relation between genotype 
and tumor microenvironment and a possibility of therapeutical intervention with ICI 
(Llosa et al., 2015; Xiao and Freeman, 2015). 
As a matter of fact, early phase trials with PD-1 blockade in patients with MSS CRC 
resulted in an absence of any immune-related objective responses (immune-related 
ORR of 0%), compared to 40% in the group of MSI patients. Moreover, the immune-
related PFS at week 20 was significantly higher in the MSI group (11% MSS vs. 78% 
MSI) (Le et al., 2015). 
To touch on a subject already raised in 1.1.2, the eminent role of microbiota in the 
immune cell / tumor cell interaction will have to be considered when discussing 
immunotherapy of CRC. To give only one example, it could be proven that some 
bacteria are able to impair NK cell-mediated anti-tumor immune responses, thus 
enabling tumor immune escape (Gur et al., 2015; Lasry et al., 2016). Even though this 
surely exceeds the topic of the dissertation thesis, such considerations with new possible 
therapeutic impacts should be followed, facing the growing awareness of the 
gastrointestinal microbiome as one of the main players in carcinogenesis. 
To put it into a nutshell, immunotherapy in CRC, especially with MSI status, depicts a 
treatment regimen worthy of being taken into account with a focus on modulation of the 
immunosuppressive tumor microenvironment. 
 
1.5. Combination of virus and immune checkpoint inhibitors in cancer therapy 
The rationale for combining virotherapy with ICI results from the experience with 
partly improvable therapeutical success with the respective monotherapies in different 
tumor entities. Synergistic effects are hoped for, since virotherapy is able to induce an 
active anti-tumor immune response inclusive of an ICI-favorable tumor micro-
environment, while immune checkpoint blockade showed to strengthen preexisting 
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immune responses by abrogating immune escape mechanisms, even creating 
immunological memory (Vile, 2014; Rajani and Vile, 2015). 
As viral-induced oncolysis leads to release of multiple foreign tumor antigens, thus 
establishing a prerequisite for activation of DCs and, following, cross-presentation of 
TAAs to T-cells in the lymph nodes, even poorly immunogenic tumors become a target 
of highly effective anti-cancer immune mechanisms (see 1.2.1). Furthermore, the 
presence of an OV itself with associated immunogenic viral antigens could serve as 
immunostimulans. But still, with the immunosuppressive mechanisms exploited by the 
tumor, including immune checkpoint ligand production, an immune response induction 
by virotherapy alone will probably not lead to long-time regression. 
 
Figure 6: Principle of combining oncolytic virus (MeV) with immune checkpoint blockade 
(atezolizumab, nivolumab) 
Tumor-specific viral infection, followed by replication and production of virions, results in 
highly immunogenic tumor cell lysis with release of antigens, which are foreign to the 
immunological self. These TAAs derive from genetic mutations or from epigenetic alterations, 
and depict potent epitopes for T-cell activation after presentation by DCs in lymph nodes. CD8+ 
CTLs, to name only one of the main actors in anti-tumor immune response, are impaired in 
their activity by PD-1 / PD-L1 checkpoint pathway, which is exploited by tumor cells for 
immune escape. Here, ICI such as atezolizumab or nivolumab interfere to strengthen and 
prolong OV-induced anti-tumor immune response. Figure modified after (Vile, 2014). 
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Gao and colleagues achieved to cure four out of five mice with peritoneal mammary 
tumor implants, using a combination therapy of recombinant replicating vesicular 
stomatitis virus (rrVSV), which was retargeted to infect Her2/neu positive cells, 
together with anti-CTLA4 mAb, whereas virotherapy alone could not induce any cure, 
but only prolong survival (Gao Y, 2009). Moreover, rechallenging trials without any 
further therapy in mice, which had received combination therapy before, resulted in 
tumor resistance: Those findings underlined the dynamic, active character of such a 
treatment regimen, obtaining immunological memory function. 
Woller et al. showed that systemic resistance against ICI therapy could be overcome by 
localized adenovirus-induced oncolysis in CMT64 lung adenocarcinomas, as an 
efficient elimination of disseminated lung tumors could be induced in mice (Woller N, 
2015). Interestingly, this CD8+ T-cell-dependent process of immune response went 
along with a broader spectrum of presented MHC class I T-cell epitopes. Moreover, it 
was proven that viral oncolysis could induce PD-L1 expression on APCs infiltrating 
cancer nodes of liver and lung, thus creating an ICI-favorable microenvironment. 
One possibility to investigate immune effects of a combination therapy in vitro was 
presented by Rajani and colleagues in a B16 melanoma cell culture model under NK 
cell coculture (Rajani K, 2016): The ICI-augmented NK cell activation by reovirus, 
resulting in improved tumor cell killing, confirmed the results of cure in a B16 model in 
immunocompetent C57Bl/6 mice after combination therapy of i.t. reovirus with i.v. 
anti-PD-1 mAb. 
With the realization of transgenic manipulation of virotherapeutics, several 
achievements were made in the subject of tumor-specific delivering of ICI, expressed 
by the virus itself with remaining oncolytic potential (Dias JD, 2012; Engeland CE, 
2014). Those results depict a possibility of not only increased efficacy, but also of 
reduction of unwanted immune-related adverse events in case of systemic ICI 
application. 
Investigating relevant effector cells mediating such a immunovirotherapy-induced anti-
tumor immune response, CD8+ T-cells as well as NK cells seem to be rudimental, but 
not CD4+ T-cell subsets (Juan J. Rojas, 2015; Rajani K, 2016). 
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But still, combination therapy implies difficulties in scheduling, as ICI-increased 
antiviral immune responses could be detrimental to viral replication when applied 
simultaneously. Rojas et al. therefore could prove the benefit of delayed ICI 
administration with regard to tumor regress and to survival in mice with renal 
adenocarcinoma, enabling an early phase of unhindered viral replication (Juan J. Rojas, 
2015).  
With those promising results from in vitro and animal model research, the first early-
phase clinical trials combining virotherapy and immune checkpoint blockade are 
already ongoing (as described in 1.2.3), and results will soon show clinical feasibility 
and response rates in the subset of the complex human immune system. 
In regard to clinical testing of immunovirotherapy in patients, one of the latest findings 
was made by Ribas and colleagues who applied combined Talimogene laherparepvec 
and pembrolizumab treatment in advanced melanoma (NCT02263508; for details, see 
1.2.3) (Ribas et al., 2017). Interestingly, taking tumor samples into account obtained 
prior to the first application of OV, response rates seemed to correlate neither with 
initial CD8+ T-cell-infiltration, nor with also frequently discussed predictive parameters 
such as PD-L1 or IFN-γ expression (Herbst et al., 2014; Tumeh et al., 2014). Especially 
in combination therapy responders, pretreatment with the herpes virotherapeutic itself 
achieved a shift towards a highly ICI-favorable tumor microenvironment, including not 
only immigration of CD8+ T-cells and enhanced expression of both PD-L1 and IFN- γ 
at the tumor site, but also a rise in CD4+ and CD8+ T-cells in blood samples. OV was 
therefore the prerequisite for implementation of a systemic anti-tumor response, 
strengthened by following ICI and OV applications - another in vivo proof of immuno-
virotherapy overcoming poor tumor immunogenicity (Ribas et al., 2017). 
 
1.6. Aim of this dissertation 
This dissertation aimed to investigate a combination therapy of measles vaccine virus 
(MeV-GFP) together with immune checkpoint blockade, targeted against PD-1 (nivolu-
mab) or PD-L1 (atezolizumab). We focused on examination of (i) whether measles OV 
could induce ICI-favorable effects in the tumor microenvironment in regard to PD-L1 
expression in CRC cell lines, (ii) synergistic therapeutical effects in the subset of CRC 
cell lines in coculture with NK cells or PBMC, namely an improved anti-tumor immune 
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response resulting in an increased tumor cell killing, and (iii) antiviral immune effects, 
considering the impact of ICI on efficient MeV-GFP replication and spread in colorectal 
tumor cells. 
Those cell culture experiments depict a necessary prerequisite to translate a combination 
treatment regimen of oncolytic measles vaccine virus and ICI influencing the PD-1 / 
PD-L1 pathway into animal models and, finally, early phase clinical trials for patients 
with advanced colorectal cancer disease. Paying attention to both anti-tumor and 
antiviral immune effects of such a combination has its eligibility in planning a future 
time schedule for a conceivable therapeutic regimen, thus respecting a possible 
impairment of measles replication by ICI-induced immune responses. 
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2. Materials and methods 
 
2.1. Cell culture of tumor cells 
2.1.1. Materials and devices for cell culture 
Table 1: Materials and devices for cell culture 
Materials and devices for cell culture  
Dulbecco’s modified Eagle’s medium 
(DMEM) (+ L-glutamine + 4.5 g / l 
glucose) 
SIGMA life science 
Dulbecco’s phosphate buffered saline 
(PBS) without Mg2+ and Ca2+ 
SIGMA life science 
Fetal calf serum (FCS) PAA Laboratories GmbH 
Opti-MEM®I + GlutaMAXTM-I Gibco by life technologiesTM 
Dimethylsulfoxide (DMSO) PanReac AppliChem 
RPMI 1640 (+ L-Glutamine + 25 mM 
HEPES) 
Gibco by life technologiesTM 
Pen Strep (Penicillin Streptomycin) Bio Whittaker, Lonza 
Recombinant Human Interleukin-2 (IL-2) ImmunoTools 
Trypsin-EDTA solution 0.25 % SIGMA life science 
Trypan Blue solution 0.4 % SIGMA life science 
Neubauer improved haemocytometer Karl Hecht Assistent GmbH 
Culture flask, 750 ml, 175 cm2 growth area Greiner Bio-One GmbH 
Culture flask, 300 ml, 75 cm2 growth area TPP  
15 ml Cellstar tubes® Greiner Bio-One GmbH 
50 ml polypropylene conical tube  Corning 
Cell strainer Greiner Bio-One GmbH 
1.5 ml safe-lock tube eppendorf 
2.0 ml safe-lock tube eppendorf 
C-Chip (disposable haemocytometer) Kisker Biotech GmbH & Co. KG 
Cryogenic vial Corning 
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Incubator for virus-free cell culture 
(HERA cell) 
Heraeus 
Incubator for virus-infected cell culture Memmert 
Megafuge 2.0 R centrifuge Heraeus SEPATECH 
Light microscope Olympus CK40 Olympus  
 
DMEM, PBS, Trypsin-EDTA and FCS were stored at 4 °C after opening, so DMEM + 
10 % FCS as well as PBS had to be incubated in the water bath at 37 °C before usage, 
while Trypsin-EDTA was warmed up at room temperature (RT). 
FCS and Trypsin-EDTA were stored frozen at -20 °C before usage. FCS had to be heat-
inactivated for 30 minutes at a temperature of 56 °C to inactivate proteins of the 
complement system. 
 
2.1.2. Used cell lines 
The used tumor cell lines derive from the National Cancer Institute NCI-60 tumor cell 
panel with the similarity of being of human colorectal carcinoma origin, but differing 
significantly in their characteristics of oncolysis resistance towards measles vaccine 
virus MeV-SCD as illustrated in the table below. African green monkey Vero cells were 
used for virus titration.  
 
Table 2: Used cell lines with their characteristics (NCI-Webpage, Accessed August 17, 
2016)  
The different NCI-60 human colorectal carcinoma cell lines differed substantially in their 
oncolysis resistance behavior after infection with MeV-SCD. 
Cell 
line 
Species Origin Doubling time 
in hours 
Oncolysis	resistance	against	MeV-SCD		
SW-620 human colorectal 
carcinoma 
20.4 intermediate 
resistant 
HT29 human colorectal 
carcinoma 
19.5 susceptible 
HCT-
15 
human colorectal 
carcinoma 
20.6 high resistant 
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Vero African green 
monkey 
kidney epithelial 
cells 
24 - 96 
(Nahapetian et 
al., 1986) 
- 
 
2.1.3. Cell culture 
Cells were cultured permanently in plastic culture flasks of 750 ml and 300 ml volume, 
being stored humidified, 37°C-tempered and with 5 % CO2 in separated incubators for 
virus-infected cells as well as uninfected cells. Moreover, cultured cells were regularly 
tested for mycoplasma contamination. 
For excellent growth in monolayers, cells were passaged every three or four days. 
Cultivation took place in Dulbecco’s Modified Eagle’s Medium, supplemented with 10 
% fetal calf serum (FCS, also fetal bovine serum / FBS), which had been heat-
inactivated at 56 °C for 30 minutes before use.  
For splitting, cells were washed with phosphate buffered saline (PBS) and then 
detached with Trypsin-EDTA. Supporting the effect of the trypsin, culture flasks were 
incubated for about five minutes at 37°C. The EDTA additionally enhanced the 
trypsinization, creating an acidic environment. Detachment of cells from the flasks’ 
bottom could be controlled by light microscopy. The trypsin was inhibited by the FCS 
in the medium, which was used to remove the cells from the flasks’ ground. The cell 
suspension was collected in falcon tubes, followed by optional centrifugation at RT, 
1000 revolutions per minute (rpm), for 4 minutes. After centrifugation, the cell pellet 
was resuspended in about 5 ml of fresh medium, depending on the pellet’s size. At last, 
the cell suspension was returned into a culture flask in ratios of 1:2 to 1:20, depending 
on the growth kinetics of the respective cell line, and filled up with fresh medium. If the 
cells empirically tended to agglutination, the cell suspension was passed through a cell 
strainer.  
 
Table 3: Different culture vessels and corresponding amounts of medium, trypsin or PBS 
Culture vessel size DMEM + 10 % FCS Trypsin-EDTA PBS for washing 
Large culture flask 
(175 cm2) 
30 ml 3 ml 10 ml 
Medium culture 15 ml 1,5 ml 10 ml 
Materials and methods 
45 
flask (75 cm2) 
6 well plate 2 ml 0.5 ml 2 ml 
24 well plate 0.5 ml 0.2 ml 0.5 ml 
 
2.1.4. Counting of cells via Neubauer haemocytometer 
To count the number of cells in a solution, a Neubauer improved haemocytometer was 
used. Therefore, cells were trypsinized and centrifuged as described above. The cell 
pellet was resuspended in DMEM + 10 % FCS. 10 µl of cell suspension was added to 
90 µl of Trypan Blue solution 0.4 % in a 1.5 ml Eppendorf cup and after vortexing, the 
haemocytometer was charged with 10 µl of the stained cell suspension.  
Cells were counted in four large quadrants, using light microscopy, and the amount of 
cells per milliliter medium was calculated by the following formula. Vital cells could be 
distinguished from dead cells, as they were bright, whereas dead cells were stained dark 
blue by trypan blue. For counting, cells which were placed either on the left or on the 
lower, but not on the right or the upper margin of the quadrant were taken into account. 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 =  𝐶𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠4 ×10×10! 
 
Cell count was divided by four and multiplied by 104 to calculate the amount of cells 
per milliliter, afterwards multiplied by 10 as the original cell suspension was diluted 
with trypan staining at 1 : 10. 
The amount of counted cells in four quadrants should not exceed 300 or go below 50 to 
make the result reliable, so dilution could be necessary. If cells were too agglutinated, 
usage of a cell strainer was required. 
For counting of virus-infected cells, disposable haemocytometer chips were used. 
 
2.1.5. Cryopreservation of cells 
Tumor cell lines were cryopreserved at -150 °C. Therefore, the cells were washed, 
trypsinized and centrifuged as described. The cell pellet was resuspended in a special 
medium for cryopreservation, consisting of FCS + 10 % DMSO (dimethylsulfoxide).  
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1 ml of the suspension was used for one aliquot, being pipetted into a labeled cryotube. 
For optimal results, the tumor cells were frozen overnight in an isopropanol-filled 
freezing box at -80 °C, before they could be stored at -150 °C. 
 
2.1.6. Thawing of cells for recultivation 
Cells were thawed by carefully warming the cryotubes in the water bath at 37°C. 
Afterwards, cells were suspended in 8 ml of preheated DMEM + 10 % FCS in a 15 ml 
falcon tube and centrifuged for 4 minutes at 1000 rpm and 20 °C. 
The supernatant was discarded before the cell pellet could be resuspended in 5 ml of 
fresh medium and the suspension was added with 10 ml of medium in a middle-sized 
culture flask, which was stored in the incubator. Cell growth was controlled the next 
day by light microscopy. The medium was exchanged if necessary. 
 
2.1.7. Seeding of cells 
Tumor cells were seeded in different culture plates at diverging cell amounts, dependent 
on the cell line’s growth characteristics. 
After being washed with PBS, trypsinized and centrifuged, the cells were counted as 
described in 2.1.4. Furthermore, the needed amount of cell suspension for the distinct 
number of wells was calculated with the formula below and replenished with DMEM + 
10 % FCS. 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑖𝑛 𝑚𝑙 =  
 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙𝐶𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠𝑚𝑙  𝑥 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑤𝑒𝑙𝑙𝑠 
 
The cell lines which tended to agglutinate were passed through a cell strainer before, a 
multi-stepper was used and the cell suspension was thoroughly resuspended with 
medium to guarantee uniformity of the cell amount in the different wells. Conformity 
could be proved via light microscopy the day after. 
The table below shows the different culture plate sizes with the needed amount of tumor 
cells. 
Materials and methods 
47 
Table 4: Different culture plates and fitting numbers of cells being seeded per well 
Cell line  HT29 SW-620 HCT-15 
Required 
number of 
cells per well 
6-well plate 3 x 105 4 x 105 3 x 105 
24-well plate 3 x 104 4 x 104 2.5 x 104 
96-well plate  5 x 103 5 x 103 2.5 x 103 
 
2.1.8. Treatment of cells with immune checkpoint inhibitors 
Immune checkpoint inhibitors (ICI) targeted against PD-1, such as nivolumab 
(Nivolumab BMS®, Bristol-Myers Squibb) or pembrolizumab (Keytruda®, MSD), and 
against PD-L1, here atezolizumab (Tecentriq®, Roche), were a kind gift of PD Dr. 
Marcus Schittenhelm, University Hospital Tübingen, and stored at 4 °C. 
The concentrations of immune checkpoint blockade antibodies used for the respective 
experiments are listed below. 
 
Table 5: Concentrations of immune checkpoint inhibitors used in different experiments 
Experiments 
Concentration of ICI 
xCELLigence 5 µg / ml 
Viral growth curves 10 µg / ml 
Determination of viral titers 5 µg / ml 
 
 
2.2. Cell culture of virus-infected cells 
2.2.1. Used virus strains 
For infection with oncolytic measles vaccine virus, two different virus strains were 
used: MeV-GFP (GFP = green fluorescent protein) and MeV-SCD (SCD = super-
cytosine deaminase, a suicide gene functioning as prodrug-converting enzyme of 5-
fluorocytosine). Virus was stored at -80 °C in aliquots of 100 µl, 200 µl and 500 µl. 
 
2.2.2. Infection of cells 
For virus infection, tumor cells were seeded the day before in DMEM +10 % FCS in 
culture plates as described in 2.1.7. 
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Uniformity of cell seeding was verified the next day by light microscopy, before cells 
were infected with virus at different multiplicities of infection (MOI). Multiplicity of 
infection describes the ratio of virus particles per target cell, meaning that infection at a 
MOI of 1 implies that one plaque forming unit (PFU) of virus is used per tumor cell. 
The formula below was used to calculate the needed amount of virus suspension in 
regard to MOI, count of cells per well, virus titer and number of wells. 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 
 = 𝑀𝑂𝐼 ×  𝑐𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙𝑣𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑒𝑟  × 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑤𝑒𝑙𝑙𝑠 
 
For infection, virus suspensions were prepared in Opti-MEM®I + GlutaMAXTM-I (in the 
following abbreviated as Opti-MEM). Therefore, aliquots with the respective virus were 
thawed at RT, carefully vortexed and pipetted into calculated volumes of Opti-MEM, 
optionally using dilution series to prepare all needed MOIs. 
Cells were washed once with preheated PBS and infected with the respective virus 
solution. At 2.5 - 3 hpi, the inoculum was removed and DMEM + 10 % FCS was added. 
Phase contrast and, for MeV-GFP, fluorescence microscopy could verify success of 
infection as described in 2.2.3.  
As a matter of laboratory safety, UV-light irradiation of cell culture materials took place 
after working with virus under the laminar flow hood for complete virus inactivation. 
 
2.2.3. Control of tumor cell infection with MeV-GFP using fluorescence microscopy 
Successful infection of tumor cells with MeV-GFP could be monitored via fluorescence 
microscopy, using the OLYMPUS IX50 with connected upstream OLYMPUS U-RFL-
T. Phase contrast and fluorescence microscopy pictures could be taken with the F-View 
Soft Imaging System and anaLYSIS software.  
The MeV-GFP-infected CRC tumor cells could be detected as green lightening cell 
syncytia, as GFP (green fluorescent protein) implicates the intrinsic ability to fluoresce 
when stimulated with blue light. Therefore, fluorescence microscopy was used to 
determine viral titers (as described in 2.8.3). 
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2.3. Cell culture of NK cells and peripheral blood mononuclear cells 
Both NK cells and peripheral blood mononuclear cells (PBMC) were isolated from 
various healthy donors and a kind gift of AG Salih, either fresh in culture or as frozen 
aliquots. We therefore thank Stefanie Maurer, AG Salih, Internal Medicine II, 
University Hospital Tübingen, for providing the immune cells. 
 
2.3.1. Cultivation of immune cells 
NK cells were cultivated in 24 well plates with 1 x 105 irradiated feeder cells in 1 ml of 
NK cell medium (RPMI-1640 with 10 % FCS, 1 % Pen Strep (Penicillin Streptomycin) 
and 2 mM L-glutamine). To protect medium from evaporation, only eight wells in the 
middle of the plate were used for NK cell cultivation, whereas the other wells were 
filled with 1 ml PBS. 
For medium exchange, 200 µl of medium were carefully exchanged by 200 µl of fresh 
medium every two days. 
NK cells were stimulated by addition of interleukin 2 (IL-2) to the medium at 25 U / ml. 
For cocultivation with tumor cells, stimulation could be omitted on the last day of 
medium exchange to decrease NK cell-induced tumor cell killing activity. 
PBMC were also cultured in fluid culture, using plastic culture flasks of different sizes 
(see 2.1.1) and the same medium used for NK cells. Storage of immune cells took place 
in a humidified and 37 °C-tempered incubator, containing 5 % of CO2. 
 
Figure 7: Schematic illustration of NK cell cultivation 
NK cell cultivation took place in 24-well plates containing 1 ml of PBS in edging wells (blue 
colored wells) for evaporation protection and 1 ml of NK cell suspension on 1 x 105 feeder cells 
in the middle wells (fawn colored wells).  
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2.3.2. Thawing of NK cells 
Frozen NK cells were stored at -150 °C until the day before cocultivation. For thawing, 
NK cells were added to fresh NK cell medium as described before (2.3.1) and were 
centrifuged for 8 minutes at 800 rpm and RT. Afterwards, cells were resuspended in 
medium, together with IL-2 for stimulation (25 U / ml), and counted. 2 x 106 NK cells 
per well were cultured overnight in 1 ml of medium, considering the PBS evaporation 
protection mentioned in 2.3.1. 
 
2.3.3. Cocultivation of tumor cells with immune cells 
For xCELLigence analysis and virus titrations, tumor cell lines HCT-15 and HT29 were 
cocultured with NK cells (or PBMC, respectively) at different effector : target ratios (E : 
T ratios). An E : T ratio of 10 : 1 means that for each tumor cell, 10 immune cells were 
used for coincubation.  
Coincubation took place in 6-well or 96-well plates at different E : T ratios, after CRC 
tumor cells had been seeded and treated in the respective regimen (for coincubation 
during xCELLigence analysis, see 2.7.4, and for coincubation for viral titrations, see 
2.9). Tumor cells were counted again on the day of coincubation, since growth of the 
cells had to be considered for exact composition of NK cell suspensions, or particular 
growth factors were calculated in test runs.  
For the next step, NK cells (or PBMC) were pooled and wells were resuspended once 
with RPMI in the case of cultivation in well plates. Afterwards, cells were counted via 
Neubauer improved haemocytometer as described in 2.1.4 after centrifugation at 1200 
rpm and RT for 4 minutes, using 10 µl of cell suspension and 90 µl of trypan blue.  
To achieve the required immune cell amount for different E : T ratios in the exact 
volume of immune cell medium, cells were centrifuged again and the cell pellet was 
resuspended in the calculated amount of RPMI. Serial dilution was used to produce the 
different E : T ratios and coculture was realized by pipetting the needed amount of 
immune cell suspension into each well of the seeded tumor cell plates with incubation 
times from 48 to 58 hours at 37 °C. 
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2.4. Quantification of PD-L1 expression on tumor cell lines via FACS analysis 
2.4.1. Materials and devices for FACS analysis  
Table 6: Materials and devices for FACS analysis 
Materials and devices for FACS analysis  
Dulbecco’s phosphate buffered saline 
(PBS) without Mg2+ and Ca2+ 
SIGMA life science 
Fetal calf serum (FCS) PAA Laboratories GmbH 
Accutase® solution SIGMA life science 
4 % paraformaldehyde (PFA) Otto Fischar GmbH 
Gamunex 10% 100 mg / ml (FC block) Talecris Biotherapeutics GmbH 
5 ml polypropylene round-bottom tube Corning 
BD CellQuestTM analysis software BD Biosciences 
BD FACSCaliburTM BD Biosciences 
AttuneTM NxT Acoustic Focusing 
Cytometer 
ThermoFisher Scientific 
Megafuge 2.0 R centrifuge Heraeus SEPATECH 
 
2.4.2. Staining antibodies for FACS analysis with their corresponding isotypes 
Table 7: Staining antibodies for FACS analysis with their corresponding isotypes 
Staining antibody Isotype 
FITC anti-human CD3 BioLegend FITC Mouse IgG1, κ 
Isotype Ctrl 
BioLegend 
FITC anti-human CD56 
(NCAM) 
BioLegend FITC Mouse IgG1, κ 
Isotype Ctrl 
BioLegend 
PE anti-human CD46 BioLegend PE Mouse IgG1, κ 
Isotype Ctrl 
BioLegend 
PE anti-human CD274 
(B7-H1, PD-L1) 
BioLegend PE Mouse IgG2b, κ 
Isotype Ctrl 
BioLegend 
PE anti-human CD279 
(PD-1) 
BioLegend PE Mouse IgG1, κ 
Isotype Ctrl 
BioLegend 
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2.4.3. Staining for FACS analysis 
For the quantitative analysis of PD-L1 expression on the CRC cells, the immunohisto-
chemical method of fluorescence-activated cell sorting (FACS) was used.  
Therefore, cells were seeded in 6-well plates and infected with MeV-GFP or MeV-SCD 
(see 2.1.7 and 2.2.2 for seeding and infection of cells). For each staining approach, 5 x 
105 tumor cells were needed. Cells were washed with PBS and detached with accutase, 
which was used instead of trypsin in case of staining of surface markers. After 8 ml of 
FACS buffer (PBS + 10 % FCS) were added to the solved cells, the suspension was 
centrifuged for 4 minutes at 1000 rpm and RT. 5 x 105 tumor cells were diluted with 3 
ml PBS in FACS tubes and centrifuged again for 5 minutes at 1000 rpm and 4 °C. 
Afterwards, the supernatant was discarded and the pellet was resuspended in 50 µl of 
FACS buffer. 10 µl of Fc-block Gamunex were added to block unspecific binding sites. 
After 5 min of incubation on ice, PE-anti-human CD274 (PD-L1) antibody was added, 
and mouse IgG2b κ was used as isotype control. One sample remained unstained each. 
Incubation was performed for 30 minutes on ice after carefully vortexing each sample. 
Then 3 ml PBS were added and cells were again centrifuged for 5 minutes at 1000 rpm 
and 4 °C. The cell pellet was finally resuspended in 200 - 500 µl FACS buffer. Cells 
were fixed with paraformaldehyde (PFA, final concentration 1.3 %) so that they could 
be stored in the refrigerator until analysis.  
 
Figure 8: Principle of immunhistochemical staining for flow cytometry 
Flow cytometry allows qualitative and quantitative analysis of expression of particular proteins, 
for example the immune checkpoint ligand PD-L1 expression on PD-L1 positive tumor cells. As 
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many proteins such as PD-L1 are not able to fluoresce intrinsically, a specific antibody with 
conjugated fluorochrome, for example phycoerythrin (PE) or fluorescein isothiocyanate 
(FITC), is used for labeling. With a laser stimulus of defined wavelength, the fluorochrome is 
able to emit light with a higher wavelength, which can be transformed by the photomultiplier 
into an electric signal. 
 
2.4.4. Procedure of FACS analysis 
For FACS measurement and analysis of PD-L1 expression in HT29 and HCT-15, the 
cytometer FACSCalibur and the program CellQuest were used. For FACS measurement 
and analysis of PD-L1 expression in SW-620, AttuneTM NxT Acoustic Focusing 
Cytometer and the corresponding analysis software were used. 
 
2.5. FACS analysis of PD-1 expression on NK cell populations from different 
healthy donors 
For analysis of CD279 (PD-1) expression on NK cell subpopulations from either 
expanded NK cells or PBMC cultures of different healthy donors, flow cytometry was 
used. The amount of PD-1 expression was analyzed to investigate preconditions for 
immune checkpoint inhibitor interaction between PD-L1 expressing tumor cells and 
PD-1 expressing immune cells. 
 
2.5.1. Staining for CD279 (PD-1) expression 
CD279 expression on CD56 positive NK cell populations in both NK cells and PBMC 
cultures was analyzed. Therefore, cells were stained with FITC anti-human CD56 as 
well as PE anti-human CD279 and with the corresponding isotype controls FITC / PE 
Mouse IgG1, κ Isotype Ctrl (all BioLegend®). 5 x 105 immune cells were used per 
stain, which were added to 2 ml of FACS buffer (PBS + 10 % FCS) and centrifuged at 
1200 rpm, RT, for 4 minutes. Afterwards, staining took place in 50 µl of FACS buffer 
together with 10 µl of Gamunex, which was incubated on ice for 5 min beforehand. 
Single stains as well as one unstained sample were prepared for fluorescence 
compensation. 
Samples were incubated for 15 min on ice and then washed with 2 ml PBS. After 
centrifugation, the stained immune cells were resuspended in 300 µl of FACS buffer. 
The samples were stored in the refrigerator until time of analysis. 
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The amount of antibody used for the staining procedure can be extracted from the table 
below. 
 
Table 8: CD279 (PD-1) FACS assay stainings and the respective amounts of antibody per 
stain 
5 x 105 NK cells or PBMC were used for one stain. 
Staining Antibody Amount of  
antibody 
Amount of FACS 
buffer 
PE and FITC isotype 
control (PBMC and 
NK cells) 
mIgG1-PE 
mIgG1-FITC 
5 µl 
1 µl 
50 µl buffer + 10 µl 
Gamunex 
PE isotype control 
(PBMC and NK cells) 
mIgG1-PE 
CD56-FITC 
5 µl 
1 µl 
50 µl buffer + 10 µl 
Gamunex 
CD279-PE staining 
(PBMC and NK cells) 
CD279-PE 
CD56-FITC 
5 µl 
1 µl 
50 µl buffer + 10 µl 
Gamunex 
Single stain FITC 
(PBMC only) 
CD3-FITC 1 µl 50 µl buffer + 10 µl 
Gamunex 
Single stain PE 
(PBMC only) 
CD46-PE 1 µl 50 µl buffer + 10 µl 
Gamunex 
Unstained (PBMC 
only) 
- - 50 µl buffer + 10 µl 
Gamunex 
 
2.5.2. Analysis of CD279 expression via flow cytometry 
For CD279 expression analysis and presentation in dot plots with quadrant stats, 
FACSCalibur and the software CellQuest were used. 
 
2.6. Investigation of anti-tumor effects via sulforhodamine B cytotoxicity assay 
Sulforhodamine B (SRB) assays were used to investigate the degree of cytotoxicity 
after treatment of adherent human tumor cells with oncolytic drugs or measles vaccine 
virus. Thereby, the measured optical density correlated with the content of proteins and 
thus with the number of surviving cells (Skehan, 1990). 
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2.6.1. Materials and devices for SRB assay 
Table 9: Materials and devices for SRB assay 
Materials and devices for SRB assay  
sulforhodamine B SIGMA® life science 
trichloroacetic acid (TCA, 10 % w/v) Carl Roth GmbH + Co. KG 
acetic acid 1 % Merck (100 %) 
Tris base solution (TBS, 10 mM) SIGMA® life science 
Tecan GENios Microplate Elisa Reader MTX lab systems 
 
2.6.2. Procedure of SRB assay 
Tumor cells were seeded in 24-well plates in each 0.5 ml DMEM +10% FCS, as 
described in 2.1.7, and treated in the respective manner in quadruplicates. 
Fixation took place at different time points, washing each well with 0.5 - 1 ml PBS and 
fixing tumor cells in 250 µl of 10 % trichloroacetic acid (TCA) afterwards, both stored 
at 4 °C. TCA fixation was used to make intracellular proteins accessible for the SRB 
staining. Incubation time was at least 30 min before TCA could be tipped and collected 
for toxic waste. The plates were washed at least four times with tap water before they 
were dried at 40 °C overnight or longer. 
Staining was conducted for ten minutes at room temperature with 250 µl of SRB 
staining solution (0.4 % w/v SRB in 1 % acetic acid), targeting the basic amino acids. 
The excess dye was washed out with 1 % acetic acid, before being dried one more time 
over night at 40 °C. 
For measurement, the dye was resolved under basic conditions (pH 10.5) in about 1 ml 
of 10 mM Tris base, depending on the intensity of the pink staining. Finally, optical 
density (OD) was determined in 96-well plates at 550 nm, using Tecan GENios Elisa 
Reader. Therefore, 80 µl per well of the dissolved suspension were pipetted into the 96-
well plate in duplicates. If the OD of a single sample was over 2.0, all samples had to be 
diluted with 10 mM Tris to ensure exact measurement. 
The cell mass of treated cells was calculated in relation to MOCK-infected or untreated 
samples. Afterwards, for each experiment, means of the resulting quadruplicates were 
calculated. Data were illustrated using GraphPad Prism 4.0 software, showing the mean 
of three experiments with calculated standard error of the mean (SEM). If only one 
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representative experiment was shown, mean and standard deviation (SD) were 
calculated.  
 
2.7. xCELLigence real-time cell proliferation assay 
The xCELLigence Real-Time Cell Analyzer was used to examine the cell growth of 
adherent tumor cell lines continuously up to 130 hours. Moreover, the interactions of 
measles vaccine virus MeV-GFP, immune checkpoint inhibitors (nivolumab, 
atezolizumab) and immune cells (NK cells or PBMC) with the different CRC cell lines 
could be evaluated quantitatively throughout measurement.  
Therefore, the xCELLigence system analyzes the change of the electric impedance, 
which is influenced by cells adhering to gold boards in 96-well electronic microtiter 
plates, so-called E-Plates, thus creating an isolating monolayer and decreasing 
impedance.  
 
Figure 9: 96-well electronic microtiter plate 
 
The system works with a calculated cell index (CI), representing the change of 
impedance in relation to the background impedance with medium only (DMEM + 10 % 
FCS). The cell index is not only affected by the count of cells, which adhere to the 
bottom of the plate, but also by their shape and viability. 
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Figure 10: Procedure of xCELLigence analysis 
The schema represents the procedure of xCELLigence analysis of CRC tumor cell lines (HT29, 
HCT-15) under the influence of MeV-GFP- or MOCK-infection 21 hours after plating of tumor 
cells. Furthermore, coculture with PBMC or NK cells and application of immune checkpoint 
blockade took place at 51 hpi. For viral infection, a total FCS concentration of 5 % per well 
was chosen. Incubation of immune cells with ICI took place in RPMI + 10 % FCS for one hour 
before cocultivation. 
 
2.7.1. Materials and devices for xCELLigence analysis 
Table 10: Materials and devices for xCELLigence analysis. 
Materials and devices for xCELLigence analysis 
Triton X-100 Roth 
atezolizumab Genentech/Roche 
nivolumab Bristol-Myers Squibb 
E-Plate 96 AACEA Biosciences Inc. 
xCELLigence Real-Time Cell Analyzer 
(RTCA) 
Roche / AACEA Biosciences Inc. 
Biosafe eco (incubator) Integra Biosciences 
 
2.7.2. Seeding tumor cells for xCELLigence analysis 
The human CRC tumor cell lines HT29 and HCT-15 had to be seeded at a density 
where they remained in an exponential growth phase during the measurement period of 
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up to 130 hours. Suitable cell numbers were determined in pretest xCELLigence runs; 
cell counts used for each tumor cell line are listed in the table below. For seeding of 
tumor cells, see 2.1.7. 
 
Table 11: Cell counts per well used for xCELLigence analysis of different CRC cell lines 
Tumor cell line Cell count per well 
HT29 5 x 103 
HCT-15 2.5 x 103 
 
The samples were analyzed in triplicates per condition and for controls in sextuplicates. 
Allocation of the samples had to be planned considering the effects of drying-out in the 
wells at the E-plate margin. Those wells were best occupied with the Triton X-100 1 % 
control, which represented a standard value for maximal tumor cell killing. 
An exemplary plan of allocation for an E-plate used for xCELLigence analysis is shown 
below. 
PBS was filled into the spaces between the wells to prevent drying-out of the wells. 
Afterwards, 50 µl of DMEM + 10 % FCS were pipetted into each well for measurement 
of the background impedance value. Tumor cells were then added in 100 µl of DMEM 
+ 2.5 % FCS, resulting in a total FCS content of 5 % for viral infection the day after. 
 
Figure 8: Allocation of sample combinations for xCELLigence analysis of HT29 CRC cells 
On the left hand side: MOCK-infected cells using 10 µl of Opti-MEM. 
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On the right hand side: MeV-GFP-infected cells (MOI 2.5). 
Orange: Control. Blue: Triton X-100 1 % control. Red: Nivolumab or atezolizumab only, 
without immune cell coincubation.  
Wells located at the margin of the E-plates were used for Triton control or for maximum one 
well per triplet to not falsify the results by drying-out. 
Abbreviations: x: MOCK; M 2.5: MOI 2.5; Ate: atezolizumab; Niv: nivolumab; A+N: 
atezolizumab and nivolumab; 20:1 / 2.5:1 / 1:1 as effector : target ratios for immune cell 
coculture. 
 
2.7.3. Infection of tumor cells for xCELLigence analysis with MeV-GFP at different 
MOIs 
Viral infection with MeV-GFP at different MOIs, namely MOI 1 (in pretest runs) or 
MOI 2.5 for HT29 and MOI 10 for HCT-15, took place in 10 µl of Opti-MEM®. For 
HT29, a MOI of 2.5 was used in further experiments, considering well size and 
infection volume different from infection modus for FACS analysis or SRB assays. 
For MOCK infection, the same amount of Opti-MEM® was pipetted into the 
corresponding wells using a new pipette tip for each step. Viral infection had to take 
place within 30 minutes to not interfere with the measurement schedule of the 
xCELLigence analyzer. 
After the incubation time of three hours, 30 µl of DMEM + 38.3 % FCS were added to 
the E-plate to achieve a FCS concentration of 10 % in a total volume of 190 µl. 
 
2.7.4. Coincubation with peripheral blood mononuclear cells or NK cells at different 
effector : target ratios and treatment with immune checkpoint inhibitors 
Coincubation with PBMC or NK cells was performed in 20 µl of RPMI + 10 % FCS 51 
hours after infection with MeV-GFP. Additionally, 20 µl of 10 % Triton X-100 were 
added to control triplets to achieve maximal tumor cell killing. 
For the coculture, PBMC or NK cells were counted with the haemocytometer as 
described in 2.1.4. Effector : target (E : T) ratios from 20 : 1 to 0.5 : 1 were calculated 
considering a growth factor for the tumor cell lines which resulted from former FACS 
experiments with MeV-GFP- or MOCK-infected cells 48 hpi or, for HT29 infected at a 
MOI of 2.5, from separately plated cells which were counted 48 hpi. The required 
number of immune cells was pipetted into Eppendorf cups, centrifuged, and 
resuspended in the needed amount of RPMI + 10 % FCS. 
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For additional treatment with ICI, the immune cells were incubated with atezolizumab, 
nivolumab or both at a concentration of 5 µg / ml one hour before coincubation.  
 
2.7.5. Evaluation of xCELLigence analysis  
For analysis of the xCELLigence measurements, RTCA Software 1.2, version 1.2.1 
(Roche) was used. Graphs were generated with GraphPad Prism 4.0. 
 
2.8. Viral growth curves of MeV-GFP on HT29 and HCT-15 tumor cells 
2.8.1. Viral infection of HT29 and HCT-15 cells for preparation of virus growth 
curves 
For the measurement of viral replication, tumor cells were seeded in 6-well plates in 2 
ml DMEM + 10 % FCS in amounts listed in the table below. The day after, infection 
with the virotherapeutic MeV-GFP was performed as described in 2.2.2, using MOIs 
also specified in the table below. 
Infection took place in 1 ml of Opti-MEM, paying attention that the plates were swayed 
approximately every 15 minutes to ensure equability of infection. At 3 hpi, cells were 
washed three times with PBS and 1 ml of DMEM + 10 % FCS was added per well. 
To analyze the influence of the checkpoint inhibitors pembrolizumab (Merck / MSD) 
and atezolizumab on viral replication, the respective drug was added directly after 
infection with the new medium in a concentration of 10 µg / ml. 
 
Table 12: Amount of tumor cells per well used for viral growth curves.  
Cells were seeded in 6-well plates in 2 ml of DMEM + 10 % FCS. 
Tumor cell line Amount of tumor cells per well MOI used for viral growth curves 
HT29 2 x 105 MOI 5 
HCT-15 2 x 105 MOI 10 
 
Directly subsequent to that, the first samples were frozen at -80°C. Supernatants were 
transferred into test tubes and cells were scraped into 1 ml of Opti-MEM and also 
transferred into test tubes. 
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This procedure was repeated after 24, 48, 72 and 96 hours. For each point of time, the 
supernatant and the cell lysate of one well was used. 
 
2.8.2. Titration for virus growth curves 
The day before the viral titration, 1 x 104 Vero cells per well were seeded in 200 µl 
DMEM + 5% FCS in 96-well plates. After controlling the uniformity of cell adherence, 
the titration of the virus samples took place. Therefore, a 96-well plate was prepared for 
the serial dilution, providing 270 µl of DMEM + 5 % FCS in each well except for the 
first row.  
The samples were thawed in the water bath, vortexed and centrifuged at 3000 rpm for 2 
minutes. The supernatants were transferred into new Eppendorf cups, and 300 µl out of 
each sample were pipetted into the first empty well of the rows of the dilution plate. 
Now, 30 µl of the first well were transferred into the well below and so forth to create 
series of 1:10 dilutions, as shown in the picture below (Fig. 11).  
The diluted virus suspensions were used to infect Vero cells in quadruplicates, using 50 
µl of suspension per well. After 96 hours of infection in the incubator, the titration could 
be evaluated using fluorescence microscopy. 
 
Figure 11: 96-well plate of dilution series for MeV-GFP virus growth curves 
1 : 10 dilution series were used for the titration of MeV-GFP virus growth curves. Therefore, 
300 µl of the collected supernatants or cell lysates were pipetted into the first row of the plate. 
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Dilution was realized by transferring 30 µl out of those into 270 µl of DMEM + 5 % FCS, 
repeating that step seven times. 
 
2.8.3. Analysis of viral growth curves 
Growth curve samples were evaluated in quadruplicates via fluorescence microscopy. 
As the GFP expressed by MeV-GFP-infected tumor cells fluoresces green, infected 
wells could be detected easily as described in 1.2.4. 
For analysis, the amount of positive wells in each quad row was listed in Excel, 
calculating the viral titer in [PFU / ml]. Therefore, titers were deduced from the 50 % 
Tissue Culture Infective Dose (TCID50), describing the virus amount needed to induce 
cytopathic effects in 50 % of infected cells, which was calculated with a formula by 
Spearman and Kärber (Spearman, 1908; Kärber, 1931). 𝑇𝐶𝐼𝐷!"𝑚𝑙  =  𝑣𝑖𝑟𝑎𝑙 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠𝑚𝑙  =  10!! !"#$%&$' !"##$!!.! ! !"#!"0.03 𝑚𝑙 𝑖𝑛𝑠𝑒𝑟𝑡𝑒𝑑 𝑣𝑖𝑟𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 
 
A single well was considered as positive in case that at least one green fluorescing 
plaque / syncytium could be observed. 
With the calculated titers, line diagrams could be designed in GraphPad Prism 4.0. 
  
2.9. Determination of viral titers on HT-29 and HCT-15 tumor cells after coculture 
with NK cells or PBMC and treatment with atezolizumab or nivolumab 
To investigate the quantitative influence of ICI therapy and immune cell cocultivation 
on viral replication and spread in CRC cell lines, virus titers were determined. 
24 hours after seeding in 6-well plates, HT29 or HCT-15 tumor cells were infected with 
MeV-GFP at MOI 1 and 10, respectively. 48 hpi, both tumor cells and PBMC or NK 
cells were separately incubated for one hour with 5 µg / ml of each atezolizumab, 
nivolumab or both. Importantly, for treatment of tumor cells with ICI, a medium 
exchange was done, replacing the old medium with 1.8 ml of fresh DMEM + 10 % 
FCS. Incubation of immune cells took place in RPMI and the needed amount of PBMC 
/ NK cells was added after one hour in a volume of 200 µl to each well. 
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For control, one well was left without coincubation or ICI treatment, one well was 
coincubated with immune cells but without ICI and one well was coincubated with 
PBMC / NK cells and treated with control IgG Gamunex. 
Both supernatants and cell lysates were frozen 48 hours after coculture at -80° C, 
proceeding as described in 2.8.1. Therefore, supernatants were additionally centrifuged 
at 4000 rpm for 4 minutes to separate and discard NK cells or PBMC from supernatants. 
 
Table 13: Cell counts, MOIs, E : T ratios and ICI concentrations used for viral titer 
determination 
Tumor cell 
line 
Amount of tumor 
cells per well 
MOI used  E : T 
PBMC 
E : T  
NK 
ICI 
concentration 
HT29 2 x 105 MOI 1  10:1 2.5:1 5 µg / ml 
HCT-15 2 x 105 MOI 10 10:1 2.5:1 5 µg / ml 
 
Titration on Vero cells and calculation of the resulting MeV-GFP titers in PFU / ml 
were performed as described in 2.8.2 and 2.8.3. Bar diagrams were designed using 
GraphPad Prism 4.0.  
 
Figure 12: Workflow of virus titer determination after coincubation with NK cells / PBMC 
and treatment with ICI 
Treatment with atezolizumab and / or nivolumab took place separately for tumor and immune 
cells, using a concentration of 5 µg / ml. 
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3. Results 
 
Aim of this dissertation thesis was to investigate a novel multimodal therapeutic 
approach for the treatment of advanced colorectal carcinoma (CRC). Thereby, a measles 
vaccine virus (MeV) virotherapeutic was combined with immune checkpoint inhibitors 
(ICI) under coculture with NK cells or peripheral blood mononuclear cells (PBMC) in 
vitro, using three CRC cell lines from the NCI-60 human tumor cell panel, i.e. cell lines 
HT29, HCT-15 and SW-620. 
For cytotoxicity analysis of the respective monotherapies, Sulforhodamine B (SRB) 
assays were performed to uncover preexisting resistances in the different tumor cell 
lines.  
After the basal expression rates of immune checkpoint ligand PD-L1 on CRC cell lines 
were investigated under different culturing conditions using flow cytometry, a next step 
was to focus on the influence of treatment with measles oncolytic virus (OV) on PD-L1 
expression. Furthermore, the existence of immune checkpoint receptor PD-1 on NK cell 
subpopulations was quantified via flow cytometry. 
The functional xCELLigence real-time cell proliferation assay was used to depict 
conceivable anti-tumor effects of our immunovirotherapeutic approach for CRC 
treatment under immune cell coculture. On the other hand, antiviral effects of immune 
checkpoint blockade were examined in a viral growth curve model and, secondly, in 
viral titrations of supernatants and lysates of measles-infected CRC cells after immune 
cell cocultivation. 
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3.1. Quantification of anti-tumor effects of monotherapeutic treatment with 
measles virotherapeutic or immune checkpoint blockade in colorectal 
carcinoma 
3.1.1. Measurement of cytotoxicity under MeV-GFP-infection in human colorectal 
carcinoma cell lines HCT-15, HT29 and SW-620 
To reveal possible preexisting resistances against the respective monotreatments, cyto-
toxic influence of MeV-GFP-infection on three human CRC cell lines from the NCI-60 
human tumor cell panel was determined by SRB cytotoxicity assays. Fixation of tumor 
cells was performed at 72 and 96 hours post infection (hpi). 
 
Figure 13: SRB cytotoxicity assays of the MeV-GFP-infected human CRC cell line HT29 
Infection of HT29 tumor cells took place at different multiplicities of infection (MOI), namely 
0.1, 0.5, 1, 5 or 10. MOCK-infected HT29 cells served as control and were equalized with 100 
% of the overall cell mass. Fixation of tumor cells took place at 72 or 96 hours post infection 
(hpi). 
Three independent experiments are shown, depicting mean and standard error of the mean 
(SEM). Analysis was performed in quadruplicates for each single experiment. For calculation 
of SEM, see 2.6. 
 
In HT29 tumor cells, MeV-GFP-infection achieved a multiplicity of infection (MOI)- 
and time-dependent reduction of tumor cell mass. Thus, HT29 turned out to be 
susceptible towards MeV-GFP-induced oncolysis, as already described by Noll et al. for 
the infection with MeV-SCD at a MOI of 1 (Noll M., 2013). Our results showed that 
viral infection at the highest MOI of 10 already reduced cell mass to an extent of 18.4 % 
± 11.4 (mean and SEM) of control at 72 hpi. After 96 hours, the cell mass residue 
decreased to a percentage of 10.6 % ± 6.7; so most tumor cells had been killed by then, 
which could also be observed via light microscopy with the dead cells being solved 
from the monolayer. 
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The HT29 tumor cell killing decreased at lower MOIs, as the trends in SRB assays 
clearly showed. Namely, referring to the lowest MOI of 0.1, tumor cell mass was only 
reduced to 88.1 % ± 3.4 of control cell mass at 72 hpi, whereupon a longer time of 
cultivation could not improve tumor cell killing in this single case with 88.7 % ± 4.8 at 
96 hpi. 
 
Figure 14: SRB cytotoxicity assays of the MeV-GFP-infected human CRC cell line HCT-
15 
Infection of HCT-15 tumor cells took place at different MOIs of 0.1, 0.5, 1, 5 or 10, respectively. 
MOCK-infected HCT-15 cells served as control and were equalized with 100 % of the overall 
cell mass. Fixation of cells took place at 72 or 96 hpi. 
Three independent experiments are shown, depicting mean and SEM. Analysis was performed 
in quadruplicates for each single experiment. For calculation of SEM, see 2.6. 
 
On the other hand, another human CRC cell line from the NCI-60 panel, HCT-15, was 
observed to be highly resistant towards MeV-GFP-induced oncolysis, also consistent 
with the results of Noll et al. for MeV-SCD. In this case, even the highest MOI of 10 
could not achieve a tumor cell mass reduction, neither at 72 hpi with 102.9 % ± 10.2 of 
control cell mass, nor at 96 hpi with 96.2 % ± 3.2 of control cell mass. 
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Figure 15: SRB cytotoxicity assays of the MeV-GFP-infected human CRC cell line SW-620 
Infection of SW-620 tumor cells took place at different MOIs of 0.1, 0.5, 1, 5 or 10, respectively. 
MOCK-infected SW-620 cells served as control and were equalized with 100 % of the overall 
cell mass. Fixation of cells took place at 72 or 96 hpi. 
Three independent experiments are shown, depicting mean and SEM. Analysis was performed 
in quadruplicates for each single experiment. For calculation of SEM, see 2.6. 
 
The last cell line depicted here, SW-620, was tested intermediate resistant to MeV-GFP-
oncolysis. 
With a remaining tumor cell mass of 58.3 % ± 2.1 (mean and SEM) at 72 hpi and of 
34.5 % ± 1.9 at 96 hpi using the highest MOI of 10, a time-dependent tumor cell mass 
reduction could be observed in SW-620. Furthermore, a MOI-dependent susceptibility 
to MeV-GFP could be proven. However, higher MOIs were necessary for effective 
tumor cell mass reduction. Namely, at 96 hpi, the remaining tumor cell mass after 
virotherapeutic treatment diminished from 99.1 % ± 0.4 for MOI 0.1 to 93.9 % ± 1.3 for 
MOI 0.5, 91.1 % ± 0.8 for MOI 1, 56.5 % ± 2.3 for MOI 5 and finally 34.5 % ± 1.9 for 
MOI 10. Whereas the MOIs of 0.1, 0.5 and 1 could not or only slightly achieve tumor 
cell killing at 72 and 96 hpi, a tumor cell mass decline could be found for the MOIs of 5 
and 10 at both times of measurement. 
To sum it up, MeV-GFP-infection achieved a MOI- and time-dependent reduction of 
HT29 and SW-620 tumor cell mass at 72 and 96 hpi in vitro. In contrast to those 
findings, the human CRC cell line HCT-15 was observed to be highly resistant to MeV-
GFP-induced oncolysis at both 72 and 96 hpi, referring to MOIs from 0.1 to 10. 
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3.1.2. Examination of cytotoxicity after treatment with immune checkpoint inhibitors 
nivolumab or atezolizumab in human colorectal carcinoma cell lines HCT-15 
and HT29 
SRB assays of human CRC cell lines HT29 and HCT-15 were performed to analyze 
possible anti-tumor effects of monotherapeutic treatment with immune checkpoint 
inhibitors nivolumab, targeted against PD-1, and atezolizumab, with PD-L1 as its target. 
Tumor cell lines HT29 (permissive to MeV oncolysis) and HCT-15 (resistant to MeV 
oncolysis) were investigated, as both were used for xCELLigence analysis in the 
following. 
HT29 
 
 
Figure 16: SRB cytotoxicity assays of HT29 tumor cells after treatment with immune 
checkpoint inhibitors atezolizumab or nivolumab 
One day after plating, HT29 and HCT-15 tumor cells were treated with 5 µg / ml of 
atezolizumab or nivolumab, or were left without ICI treatment after a medium exchange, 
respectively. At each 24, 48, 72 and 96 hours after treatment, cells were fixed and prepared for 
SRB analysis. 
Means ± SD of the cell mass relative to control cell mass of untreated cells are shown. Analysis 
was performed in quadruplicates. One representative experiment is depicted. 
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HCT-15 
 
 
Figure 17: SRB cytotoxicity assays of HCT-15 after treatment with immune checkpoint 
inhibitors atezolizumab or nivolumab 
 
Monotherapeutic treatment of both CRC cell lines HT29 and HCT-15 with 5 µg / ml of 
ICI nivolumab or atezolizumab, respectively, did not influence tumor cell viability in 
vitro, neither increasing nor decreasing the remaining cell mass at 24, 48, 72 or 96 hours 
after treatment.  
According to these observations and to our expectations, both drugs were not found to 
possess independent anti-tumor efficacy in the absence of immune cells, as no PD-1 / 
PD-L1 interaction could take place. 
 
3.2. Analysis of PD-L1 expression on different human colorectal carcinoma cell 
lines under the influence of measles-induced oncolysis 
As immune checkpoint ligand (PD-L1) expression on tumor cells and immune 
checkpoint receptor (PD-1) expression on immune cells both display key factors for a 
possible therapeutic ICI interaction, these parameters were investigated in further steps. 
Thereby, a focus was set on the influence of measles virotherapeutic-infection on the 
expression of PD-L1 on human CRC cell lines at first. 
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3.2.1. Basal PD-L1 expression in human colorectal carcinoma cell lines HT29, HCT-
15 and SW-620 under the influence of different culturing conditions 
As a standard of comparison, basal expression rates of the immune checkpoint ligand 
PD-L1 on tumor cell lines HT29, HCT-15 and SW-620 were investigated via FACS 
analysis, taking different culturing conditions into account. 
On the one hand, cells were cultured in DMEM + 10 % FCS, and on the other hand, 
cells were additionally incubated for three hours in the virus incubator with Opti-MEM, 
which was normally used for viral infection. 
	  
	  
Figure 18: FACS analysis of the basal PD-L1 expression on human colorectal carcinoma 
cell lines HT29, HCT-15 and SW-620 under different culturing conditions 
Tumor cells were plated and incubated with Opti-MEM in the virus incubator, similarly to the 
process of viral infection, or were left in DMEM + 10 % FCS in the incubator for uninfected 
cells instead. After three hours of incubation, medium was replaced by fresh DMEM + 10 % 
FCS in each case. 24 or 48 hours later, cells were collected for FACS staining of PD-L1 with 
PE anti-human CD274 (PD-L1). In case of HT29 and HCT-15, three independent experiments 
were performed, showing means ± SD of the percentages of PD-L1 expressing tumor cells. 
Regarding SW-620, one representative experiment is shown. W/o = without. 
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The three human CRC cell lines showed different degrees of basal PD-L1 expression. In 
detail, 14.8 % of HT29 cells, 2.8 % of HCT-15 cells and 2.6 % of SW-620 cells were 
found to express PD-L1 without addition of Opti-MEM. 
Moreover, PD-L1 expression of the three tumor cell lines reacted differently in regard 
to time of culturing and variation of used media. In SW-620 tumor cells, a time-
dependent increase in expression of PD-L1 could be observed (24 versus 48 hours of 
cultivation), namely a difference of 9.7 percentage points in cells cultured without Opti-
MEM (from 2.6 % of analyzed tumor cells to 12.3 %) and a difference of 1.0 percentage 
points in cells cultured including Opti-MEM incubation (from 3.5 % of analyzed tumor 
cells to 4.5 %). 
In the HCT-15 tumor cell line, an increase in PD-L1 expression with respect to duration 
of culture (24 versus 48 hours) could be observed, just as described for SW-620, namely 
a difference of 4.5 percentage points in cells cultured without Opti-MEM (from 2.8 % ± 
0.7 of analyzed tumor cells to 7.3 % ± 1.3) and a difference of 6.2 percentage points in 
cells cultured with Opti-MEM incubation (from 3.4 % ± 2.3 of analyzed tumor cells to 
9.6 % ± 2.1). 
An inverse effect could be found addressing HT29 tumor cells, where a time-dependent 
decrease in expression of PD-L1 could be observed, namely a difference of 6.5 
percentage points in cells cultured without Opti-MEM (from 14.8 % ± 1.9 of analyzed 
tumor cells to 8.3 % ± 0.8) and a difference of 8.6 percentage points in cells cultured 
including Opti-MEM incubation (from 22.5 % ± 2.3 of analyzed tumor cells to 13.9 % 
± 4.7). 
In HT29, a difference of PD-L1 expression could be observed when comparing the 
different culturing conditions DMEM + 10 % FCS versus Opti-MEM. A higher PD-L1 
expression was observed when cells were cultured in Opti-MEM with a difference of 
7.7 percentage points in cells collected after 24 hours (14.8 % ± 1.9 of tumor cells 
without Opti-MEM versus 22.5 % ± 2.3 of cells with Opti-MEM incubation) and a 
difference of 5.6 percentage points in cells collected after 48 hours (8.3 % ± 0.8 of 
analyzed tumor cells without Opti-MEM versus 13.9 % ± 4.7 of cells with Opti-MEM 
incubation). 
In HCT-15 as well as SW-620, no consistent difference in expression of PD-L1 with 
respect to different culturing conditions could be observed. A decrease of PD-L1 
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expression in SW-620 from 12.3 % of analyzed CRC cells without Opti-MEM to 4.5 % 
of cells with Opti-MEM incubation after 48 hours could not be reproduced for the first 
time of measurement after 24 hours. 
To summarize, culturing conditions with regard to medium and time of culturing could 
partly influence PD-L1 expression on human CRC cell lines, but not homogeneously in 
all three tested tumor cell lines. 
These pretests were of relevance to appraise whether in the following experiments 
infection with oncolytic measles vaccine virus was a reason for a change in PD-L1 
expression rates, or whether different culturing conditions pretended such an effect. 
 
3.2.2. PD-L1 expression in human colorectal carcinoma cell lines HT29, HCT-15 and 
SW-620 after infection with MeV-GFP 
After comparison of basal PD-L1 expression rates under different culturing conditions, 
FACS analysis of MeV-GFP-infected tumor cells HT29, HCT-15 and SW-620 was 
performed to examine the influence of viral infection on the expression of the immune 
checkpoint ligand. 
MeV-GFP as a virotherapeutic implicates the advantage that the viral infection of tumor 
cells can be quantified, as infected cells express the green fluorescent protein (GFP), 
which in turn can be detected by flow cytometry. First of all, appropriate viral infection 
of the three human CRC cell lines was proven by flow cytometry. 
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Figure 19: FACS analysis of GFP expression on MOCK- or MeV-GFP-infected human 
colorectal carcinoma cell lines HT29, HCT-15 and SW-620 
Tumor cells were infected with MeV-GFP using different MOIs of 1, 5 or 10, or were MOCK-
infected. Tumor cells were fixed for FACS analysis at 24 and 48 hpi. 
The percentages of GFP positive cells are given, representing successfully infected tumor cells. 
 
Time- and MOI-dependent MeV-GFP-infection could be proven in all three CRC cell 
lines by measuring GFP expression of infected tumor cells. 
Addressing HT29 cells infected at a MOI of 1, only 39.5 % of tumor cells at 24 hpi and 
95.2 % at 48 hpi revealed GFP expression. Referring to infection at the higher MOI of 
5, 72.1 % of cells expressed GFP at 24 hpi, further increasing to 98.3 % at 48 hpi. 
In contrast to this, only 12.0 % of HCT-15 tumor cells showed GFP expression at 24 hpi 
and 31.1 % at 96 hpi, albeit the higher MOI of 10 was used for infection.  
In SW-620 cells, a MOI of 5 achieved infection of 62.5 % of tumor cells at 24 hpi and 
99.5 % at 48 hpi. With an increase of MOI to 10, infection rates could be further 
augmented to 84.1 % of tumor cells at 24 hpi and stayed at a high level of 99.9 % at 48 
hpi. These observations seemed consistent with the different MeV-GFP susceptibilities 
found in SRB assays before. 
In a next step, PD-L1 expression on infected tumor cells was analyzed. 
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A) PD-L1 expression on HT29 tumor cells, infected with MeV-GFP 
 
 
 
A) PD-L1 expression on HT29 tumor cells, infected with MeV-GFP 
24 hpi GFP 
positive 
[%] 
PD-L1 
positive 
[%] 
GFP and PD-
L1 positive 
[%] 
48 hpi GFP 
positive 
[%] 
PD-L1 
positive 
[%] 
GFP and 
PD-L1 
positive [%] 
MOCK 0.37 46.58 0.37  1.09 42.27 0.98 
MOI 1 39.52 52.03 19.59  95.20 76.71 73.63 
MOI 5 72.06 62.68 44.82  98.32 80.86 79.68 
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B) PD-L1 expression on HCT-15 tumor cells, infected with MeV-GFP
 
 
 
B) PD-L1 expression on HCT-15 tumor cells, infected with MeV-GFP 
24 hpi GFP 
positive 
[%] 
PD-L1 
positive 
[%] 
GFP and PD-
L1 positive 
[%] 
48 hpi GFP 
positive 
[%] 
PD-L1 
positive 
[%] 
GFP and 
PD-L1 
positive [%] 
MOCK 0.04 2.31 0.04  0.09 3.38 0.09 
MOI 10 12.01 2.43 0.16  31.09 20.80 10.32 
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C) PD-L1 expression on SW-620 tumor cells, infected with MeV-GFP 
 
 
Figure 20, A - C: FACS analysis of PD-L1 expression on MeV-GFP-infected in 
comparison to MOCK-infected human colorectal cancer cell lines HT29, HCT-15 and SW-
620 
MeV-GFP-infection of CRC cells was performed using different MOIs (MOI 1 and MOI 5 for 
HT29, MOI 10 for HCT-15 and MOI 5 and MOI 10 for SW-620) or cells were MOCK-infected. 
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Tumor cells were analyzed for PD-L1 expression at 24 and 48 hpi. Staining was performed with 
PE anti-human CD274 (aPD-L1 PE) or the respective PE IgG2b isotype control (isotype). In 
the dot plots of HT29 and HCT-15, percentages of PD-L1 positive cells are given irrespective of 
GFP expression status. In the dot plots of SW-620, the percentages of cells in each quadrant 
region are shown. 
 
Table 14, A - C: FACS analysis of PD-L1 expression on MeV-GFP-infected in comparison 
to MOCK-infected human colorectal cancer cell lines HT29, HCT-15 and SW-620 
The respective tables below list the percentages of GFP positive, PD-L1 positive and both GFP 
and PD-L1 positive tumor cells, referring to cells labeled with PE anti-human CD274. 
C) PD-L1 expression on SW-620 tumor cells, infected with MeV-GFP 
24 hpi GFP 
positive 
[%] 
PD-L1 
positive 
[%] 
GFP and PD-
L1 positive 
[%] 
48 hpi GFP 
positive 
[%] 
PD-L1 
positive 
[%] 
GFP and PD-
L1 positive 
[%] 
MOCK 0.25 3.48 0.17  0.42 4.48 0.29 
MOI 5 62.53 4.08 2.72  99.48 10.06 9.97 
MOI 10 84.09 3.60 2.86  99.93 7.19 7.16 
 
In HT-29 cells, PD-L1 expression 24 hpi increased from an initial level of 46.6 % of 
uninfected cells to a level of 62.7 % of cells infected at MOI 5. Further augmentation of 
PD-L1 expression could be observed at 48 hpi, finally reaching a level of 80.9 % of 
cells infected using MOI 5. 
In HCT-15, PD-L1 expression at 24 hpi did not change from an initial level of 2.3 % of 
MOCK-infected cells to a level of 2.4 % of cells infected at MOI 10, but an increase in 
PD-L1 expression could be observed at 48 hpi, finally reaching a level of 20.8 % of 
cells infected using MOI 10. 
In SW-620 cells, PD-L1 expression at 24 hpi could not be increased by MeV-GFP 
infection, with 3.5 % of uninfected cells expressing PD-L1 compared to 3.6 % of cells 
infected at MOI 10. Nevertheless, augmentation of PD-L1 expression could be observed 
at 48 hpi with 4.5 % of uninfected cells expressing PD-L1 versus 7.2 % of cells infected 
at MOI 10. However, no MOI-dependent relation of PD-L1 upregulation could be 
described, as even 10.1 % of tumor cells infected at MOI 5 expressed PD-L1 at 48 hpi. 
To sum it up, a MOI- and time-dependent upregulation of PD-L1 could be shown for 
HT29 and HCT-15 CRC cells. In SW-620, a greater proportion of MeV-GFP-infected 
tumor cells expressed PD-L1 than of uninfected tumor cells, but no MOI-dependency 
could be proven. Still, the PD-L1 expression in SW-620 rose with time of cultivation 
after OV infection. 
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As high levels of GFP expression unfortunately interfered with the PE fluorochrome, 
the percentage of PE positive cells increased in MeV-GFP-infected isotype controls as 
well. This has to be taken into account when considering results of PD-L1 expression, 
especially in the MeV-GFP susceptible cell line HT29, where high GFP expression 
levels were achieved with MOIs of up to 5 (see Fig. 19). Therefore, after effective 
infection was proven, MeV-SCD (not encoding the GFP marker gene) was used for 
measurement of PD-L1 expression in further experiments to avoid interference. 
 
3.2.3. PD-L1 expression in human colorectal carcinoma cell lines HCT-15, HT29 and 
SW620 after infection with MeV-SCD 
In a next step, the influence of MeV-SCD-infection on PD-L1 expression on human 
CRC cell lines was examined by flow cytometry, whereupon the interference of 
fluorescing GFP with PE fluorochrome, as described in 3.2.2, could be avoided. 
A) PD-L1 expression on HT29 cells, infected with MeV-SCD 
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B) PD-L1 expression on HCT-15 cells, infected with MeV-SCD
 
 
 
PD-L1 expression, HCT-15, 24 / 48 hpi with MeV-SCD at different MOIs
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C) PD-L1 expression on SW-620 cells, infected with MeV-SCD 
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Figure 21, A - C: FACS analysis of PD-L1 expression on MeV-SCD-infected in 
comparison to MOCK-infected human colorectal cancer cell lines HT29, HCT-15 and SW-
620 
MeV-SCD-infection of CRC cells was performed using different MOIs (MOI 1 or MOI 5 for 
HT29, MOI 10 for HCT-15 and MOI 5 or 10 for SW-620), or cells were MOCK-infected. 
Staining for PD-L1 analysis was performed at 24 or 48 hpi. Tumor cells were labeled with PE 
anti-human CD274 (aPD-L1 PE) or the respective PE IgG2b isotype control (isotype). In the 
graphs of HT29 and HCT-15, percentages of PD-L1 positive tumor cells, which were covered 
by the marker M1, are given. In the graphs of SW-620, percentages of PD-L1 positive tumor 
cells, covered by the region R1, are given.  
 
Comparable to our results for MeV-GFP, we could show that infection with MeV-SCD 
increased PD-L1 expression in all three human CRC cell lines in vitro. Expression 
further rose with augmentation of MOI and time of culture after infection for HT29 and 
HCT-15, whereas in SW-620, expression rose with increase of MOI but not with 
augmentation of time of culturing after infection with MeV-SCD. 
In HT29, an initial PD-L1 expression of 39.4 % of analyzed tumor cells at 24 hours 
after MOCK-infection could be increased to 56.6 % of tumor cells by MeV-SCD 
infection, using a MOI of 5. At 48 hpi, the initially lower level of PD-L1 positive HT29 
cells, namely 25.3 % of analyzed MOCK-infected tumor cells, could be enhanced to a 
PD-L1 expression on 75.3 % of cells via MeV-SCD-infection at MOI 5, thus PD-L1 
expression could be tripled by MeV treatment. Similar tendencies were observed with 
infection at a lower MOI of 1 (see Fig. 21, A). 
In HCT-15, an initially very low PD-L1 expression level of 5.9 % of MOCK-infected 
tumor cells was augmented to 9.7 % of tumor cells by MeV-SCD-infection at MOI 10, 
analyzed at 24 hpi. At 48 hpi, the slightly increased level of 10.5 % in MOCK-infected 
cells mounted to 35.6 % by OV treatment, thus again, PD-L1 expression rate even more 
than tripled. 
PD-L1 expression, SW-620, 24 / 48 hpi with MeV-SCD at different MOIs
MOCK MOI 5 MOI 10
0
20
40
60
80
Pe
rc
en
ta
ge
 o
f c
el
ls
ex
pr
es
si
ng
 P
D
-L
1
24 hpi
48 hpi
Results 
83 
Finally, in SW-620 tumor cells, an initial PD-L1 expression of 29.8 % of analyzed cells 
was increased to 53.1 % 24 hpi at MOI 5 and further to 61.6 % at MOI 10. Referring to 
measurements at 48 hpi, an initial expression of 3.4 % of SW-620 tumor cells rose to 
11.1 % at MOI 5 and to 13.2 % at MOI 10. Surprisingly, for SW-620 tumor cells, the 
dependency on time of culturing after OV infection was this time inverse in comparison 
to HT29 and HCT-15, as the PD-L1 expression in SW-620 CRC cells declined at 48 hpi 
for MOCK and both MOIs (see Fig. 21, C). However, this effect of decreased PD-L1 
expression rates after an augmented time of cultivation could not be reproduced in our 
experiments comparing different culturing media (Fig. 18) or analyzing PD-L1 
expression rates after MeV-GFP infection (Fig. 20 C). 
Summing up, those in vitro findings of PD-L1 expression analysis after infection with 
MeV-SCD confirmed our hypothesis, based on experiments with MeV-GFP (described 
in 3.2.2), that measles OV infection could consistently increase expression of immune 
checkpoint ligand on all three CRC cell lines. Hence, these results promise success of 
an immunovirotherapeutic treatment approach for colorectal cancer, blazing a trail for 
ICI application by PD-L1 upregulation through MeV-treatment. Even the tumor cell 
line with very low basal PD-L1 expression rates, HCT-15, which, at the same time, had 
to deal with the highest MeV resistance rates, achieved PD-L1 expression rates of 35.6 
% at 48 hpi with MeV-SCD at MOI 10, increased from only 5.9 % for MOCK-infected 
cells at 24 hpi. 
Moreover, referring to HT29 tumor cells, the effect of PD-L1 upregulation via treatment 
with measles virotherapeutic could also compensate the trend of lower PD-L1 
expression rates due to longer time of cultivation. Effects are visible when comparing 
measurement at 24 and 48 hours after treatment with MeV or MOCK-infection, as 
depicted in Fig. 18, 20 A and 21 A. Referring to the effects of Opti-MEM incubation 
instead of cultivation in standard DMEM + 10 % FCS medium (see 3.2.1), PD-L1 
expression on HT29 tumor cells was augmented about 1.7-fold by Opti-MEM, whereas 
MeV-SCD-infection could even triple PD-L1 expression rates, both analyzed at 48 
hours after infection or after Opti-MEM incubation. 
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3.3. FACS analysis of PD-1 expression on NK cell populations from different 
healthy donors 
PD-1 / PD-L1 interaction displays the therapeutic target for both immune checkpoint 
inhibitors nivolumab and atezolizumab. Thus, after upregulation of PD-L1 on human 
CRC cell lines HT29, HCT-15 and SW-620 through MeV-GFP- as well as MeV-SCD-
infection could be proven, expression of immune checkpoint receptor PD-1 on CD56 
positive NK cell populations was investigated. NK cells and PBMC were a friendly gift 
from AG Salih, Tübingen, and had been isolated from four different healthy donors, 
labeled #1 to #4. Furthermore, NK cells from donor #3 and PBMC from donor #2 were 
used for coincubation in xCELLigence analysis of HCT-15 tumor cells later (Fig. 24 A 
- G). 
PD-1 expression on NK cell populations from different healthy donors
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Figure 22: FACS analysis of PD-1 expression on NK cell populations from different 
healthy donors 
PD-1 expression was analyzed on CD56 positive NK cell subsets from NK cells or from 
cultured PBMC, both from different healthy donors identified with #1 to #4. NK cell subsets 
were stained with FITC anti-human CD56 and PE anti-human CD279 (PD-1) or the respective 
FITC / PE IgG1 isotype controls. In the dot plots, percentages of both CD56 and PD-1 positive 
cells are given. 
 
Table 15: FACS analysis of PD-1 expression on NK cell populations from different healthy 
donors 
The percentages of CD56 positive, PD-1 positive and both CD56 and PD-1 positive cells are 
given. 
 CD56 positive [%] PD-1 positive [%] CD56 and PD-1 positive [%] 
PBMC #1 2.33 15.1 0.16 
PBMC #2 8.32 11.59 0.27 
NK #3 87.17 2.45 0.56 
NK #4 36.72 3.51 0.76 
 
FACS analysis of PBMC from donor #1 resulted in 2.3 % of CD56 positive cells, 
representing a NK cell subset; but only 0.2 % of analyzed cells were also positive for 
PD-1. Altogether, 15.1 % of PBMC expressed PD-1. 
PBMC from donor #2 showed a higher proportion of CD56 positive cells, namely 8.3 % 
of cells; but again, only 0.3 % of analyzed PBMC were simultaneously expressing PD-1 
and CD56. From the whole entity of PBMC, 11.6 % were positive for PD-1. 
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The NK cells from donor #3 consisted of 87.2 % of CD56 positive cells; and 0.6 % of 
these were also positive for PD-1. PD-1 expression of the overall cell population was 
measured in 2.5 % of investigated cells. 
The NK cells from donor #4 possessed only 36.7 % CD56 positive cells, maybe as a 
result of a shorter time of cultivation after preparation from blood samples. 0.8 % of 
these NK cells were double positive for CD56 and PD-1, whereas 3.5 % of the whole 
cell population was only PD-1 positive. 
Summing up, neither the CD56 positive cell subset of PBMC nor the CD56 positive 
expanded NK cells were found to have more than 1 % of PD-1 positive cells as a pre-
condition to take place in a direct PD-1 / PD-L1 interaction. Yet, it should be considered 
that only the CD56 positive NK cell subset was investigated for PD-1 expression. 
Namely, PD-1 expression on overall PBMC or NK cells ranged from 2.5 % to 15.1 %. 
 
3.4. In vitro therapeutic effects of combining MeV-GFP with immune checkpoint 
inhibitors and immune cell coculture in human colorectal carcinoma cell lines 
xCELLigence real-time cell proliferation assay was used for analysis of the anti-tumor 
effects of the three different therapeutics measles vaccine virus, immune cells and ICI in 
monotherapy, as well as the effects of combined treatment with (i) measles vaccine 
virus plus ICI, (ii) measles vaccine virus plus immune cells, (iii) immune cells plus ICI 
and (iv) measles vaccine virus plus immune cells plus ICI. 
For analysis, the two human CRC cell lines HT29 and HCT-15 were chosen, 
representing a MeV-GFP-susceptible as well as a MeV-GFP-resistant tumor cell line. 
The suitable tumor cell counts for the E-plates, MOIs as well as effector : target (E : T) 
ratios were established in multiple test runs (not shown here). For cell counts, it had to 
be taken into account that tumor cells remained in an exponential growth phase over the 
measurement period of 130 hours. MOIs as well as E : T ratios were selected 
accordingly that monotherapy did not lead to a complete tumor cell killing, making it 
possible to observe potential additional therapeutic effects of the combined treatment 
approaches. 
The influence of MHC mismatch between human tumor cell lines and different healthy 
immune cell donors posed a problem in examination of the suitable E : T ratios and had 
to be considered when comparing individual xCELLigence runs. 
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3.4.1. xCELLigence real-time cell proliferation assay for analysis of HT29 / HCT-15 
growth and viability under the influence of MeV-GFP-infection together with 
nivolumab and / or atezolizumab treatment 
First of all, it was examined whether addition of ICI nivolumab or atezolizumab alone 
could improve therapeutic effects in uninfected CRC cells or in tumor cells infected 
with the virotherapeutic MeV-GFP. 
In general, a supposable improvement of therapeutic effect has to be equated with a 
decrease of the cell index (CI), being influenced by tumor cell growth as well as tumor 
cell viability over the measurement period as described in 2.7. 
A) HT29 (5.000 cells / well), infected with MeV-GFP (MOI 2.5) or MOCK-infected, 
together with ICI atezolizumab or nivolumab 
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B) HCT-15 (2.500 cells / well), infected with MeV-GFP (MOI 10) or MOCK-infected, 
together with ICI atezolizumab or nivolumab 
 
Figure 22 A - B: xCELLigence real-time assay of HT29 and HCT-15 growth and viability 
under treatment with MeV-GFP and / or immune checkpoint inhibitors 
xCELLigence real-time cell monitoring assay was used to investigate growth and viability of 
CRC cells over a period of 130 hours under the influence of treatment with MeV-GFP, ICI, or a 
combination of both. 21 hours after plating of tumor cells, infection with MeV-GFP at the 
respective MOI (MOI 2.5 for HT29 and MOI 10 for HCT-15) or MOCK infection took place. 51 
hpi, nivolumab or atezolizumab were added in a concentration of 5 μg / ml each. 
The cell index (CI) is shown as a function of time. Measurement took place in triplets; means 
and SD are shown. For each tumor cell line, one representative experiment is shown. 
Niv = nivolumab, Ate = atezolizumab, MeV = MeV-GFP. 
 
In HT29, treatment with the measles virotherapeutic MeV-GFP more than halved the 
colorectal tumor cell growth and viability in comparison to controls after 130 hours. 
Relating to the addition of ICI to uninfected tumor cells, curves of atezolizumab and 
nivolumab were almost identical. A slight trend towards CI decrease compared to the 
control curve could be observed. The same applied for ICI addition to MeV-GFP-
infected HT29 tumor cells, where only a trend of CI decrease could be recorded by both 
atezolizumab and nivolumab. 
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To recapitulate, neither atezolizumab nor nivolumab could achieve a significant 
impairment of HT29 tumor growth and viability in a model without immune cells, as 
expected. 
In HCT-15, similar results could be observed. Addition of MeV seemed to change 
growth kinetics throughout measurement: Between 21 hours and about 80 hours after 
start of xCELLigence recording, the MeV curve rose earlier than the MOCK curve, 
whereas in the period between 80 hours and 130 hours, the steepness of the MeV curve 
clearly decreased in comparison to MOCK control. Thus, after 130 hours of 
measurement, the CI of infected tumor cells was almost halved in comparison to 
control, although HCT-15 had been considered highly resistant to MeV-GFP-mediated 
oncolysis in SRB assays (displayed in 3.1.1). 
In uninfected HCT-15, addition of each nivolumab and atezolizumab lead to a decrease 
of CIs, but in both cases less than the CI reduction achieved through measles infection. 
Results of uninfected HCT-15 tumor cells treated with atezolizumab should be regarded 
under reserve, referring to the range of SD. In MeV-GFP-infected tumor cells, no 
impairment of growth and viability by ICI could be recorded, as the two curves of ICI-
treated HCT-15 cells (yellow for nivolumab and dark blue for atezolizumab) were equal 
to that of the infected control (light green for MeV-GFP only). 
To put it into a nutshell, xCELLigence analysis of HCT-15 could show a CI decrease 
through MeV treatment and a trend of CI reduction through ICI treatment in uninfected 
tumor cells, but no consistent CI decrease through ICI in MeV-GFP-infected tumor 
cells. 
 
3.4.2. xCELLigence real-time cell proliferation assay for analysis of HT29 / HCT-15 
growth and viability under the influence of MeV-GFP-infection, treatment with 
nivolumab and / or atezolizumab and PBMC or NK cell coculture 
As previously performed without immune cells, the anti-tumor effects of our treatment 
approach with MeV and / or ICI were now investigated in human CRC cells under the 
influence of cocultivation with PBMC or NK cells. Thus, a PD-1 / PD-L1 interaction 
between tumor and immune cell was permitted, depicting a therapeutic possibility for 
ICI intervention. 
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A) HT29 (5.000 cells / well), infected with MeV-GFP (MOI 2.5) or MOCK-infected, 
together with ICI atezolizumab and PBMC (E : T = 20 : 1) 
 
B) HT29 (5.000 cells / well), infected with MeV-GFP (MOI 2.5) or MOCK-infected, 
together with ICI nivolumab and PBMC (E : T = 20 : 1)
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C) HT29 (5.000 cells / well), infected with MeV-GFP (MOI 2.5) or MOCK-infected, 
together with ICI atezolizumab and nivolumab and PBMC (E : T = 20 : 1) 
 
D) HT29 (5.000 cells / well), infected with MeV-GFP (MOI 2.5) or MOCK-infected, 
together with ICI atezolizumab and NK cells (E : T = 2.5 : 1) 
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E) HT29 (5.000 cells / well), infected with MeV-GFP (MOI 2.5) or MOCK-infected, 
together with ICI nivolumab and NK cells (E : T = 2.5 : 1) 
 
F) HT29 (5.000 cells / well), infected with MeV-GFP (MOI 2.5) or MOCK-infected, 
together with ICI atezolizumab and NK cells (E : T = 1 : 1) 
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G) HT29 (5.000 cells / well), infected with MeV-GFP (MOI 2.5) or MOCK-infected, 
together with ICI nivolumab and NK cells (E : T = 1 : 1) 
 
Figure 23, A - G: xCELLigence real-time assay of HT29 growth and viability under 
treatment with MeV-GFP, immune checkpoint inhibitors and PBMC / NK cells 
xCELLigence real-time assay was used to investigate growth and viability of human CRC cells 
over a period of 130 hours under influence of a combination of MeV-GFP, treatment with ICI 
and PBMC or NK cell coculture.  
21 hours after plating of 5.000 HT29 tumor cells per well, infection with MeV-GFP at MOI 2.5 
or MOCK infection took place. 51 hpi, NK cells or PBMC, which both had optionally been 
incubated with 5 μg / ml of nivolumab and / or atezolizumab one hour before, were added at 
an E : T ratio of 20 : 1 for PBMC and 2.5 : 1 and 1 : 1 for NK cells. For control, 5 μg / ml 
atezolizumab or nivolumab were added without immune cell coincubation. PBMC and NK cells, 
as described in 2.3, had been purified from different healthy donors before and were a kind gift 
of AG Salih. 
Triton X-100 1 % was used as a positive control for maximal tumor cell lysis. 
The cell index (CI) is shown as a function of time. Measurement took place in triplets; means 
and SD are shown. For each tumor cell line, one representative experiment is shown. 
Niv = nivolumab, Ate = atezolizumab, MeV = MeV-GFP, NK = NK cells. 
 
In comparison to anti-tumor effects of measles virotherapeutic, the addition of PBMC at 
51 hpi to uninfected HT29 CRC cells at an E : T ratio of 20 : 1 achieved an even higher 
grade of tumor cell mass and viability reduction in the respective xCELLigence run (see 
Fig. 23, A). Furthermore, PBMC together with MeV-GFP treatment even reached CI 
levels of the Triton X-100 1 % curve at about 100 hours after start of measurement, 
which displayed the control for maximal tumor cell killing. 
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Nevertheless, the further addition of the ICI atezolizumab under PBMC coincubation 
could improve tumor cell killing neither in uninfected, nor in MeV-infected HT29 
colorectal tumor cells (see Fig. 23, A). 
The same observations were made for nivolumab, the antibody targeted against PD-1, 
where ICI addition could again not further diminish HT29 tumor cell proliferation in 
comparison to treatment approaches with PBMC only, or PBMC together with 
oncolytic MeV-GFP (see Fig. 23, B). 
Finally, referring to a combination therapy of atezolizumab and nivolumab, thus 
targeting both, immune checkpoint ligand as well as receptor, ICI addition was again 
comparable in its therapeutic effects to treatment with PBMC only or PBMC plus 
measles OV-infection (see Fig. 23, C). 
Still, it should be considered that in the case of PBMC, possible therapeutic effects were 
rather exhausted, as the combination therapy consisting of immune cell coincubation 
together with MeV-GFP-treatment already achieved HT29 tumor cell reduction to a 
level of Triton X-100 1% control. 
NK cell coincubation at an E : T ratio of 2.5 : 1 was examined next (see Fig. 23, D). 
Here, in comparison to PBMC addition, NK cells also reduced HT29 tumor cell mass 
and viability, especially in a first period up to about 80 hours after start of measurement 
(8 hours after addition of NK cells), whereas in a second period until the end of 
measurement after 130 hours, the CI increased again with prevailing HT29 tumor cell 
growth. Hence, in contrast to PBMC coincubation at E : T = 20 : 1, less HT29 tumor 
cell killing was observed through addition of NK cells at E : T = 2.5 : 1, keeping in 
mind the descent of different donors and, thus, diversity of MHC mismatch. 
Similar to PBMC, NK cell coincubation of MeV-GFP-infected HT29 tumor cells even 
further decreased tumor cell mass over the whole measurement period. In contrast to 
NK cell coincubation only, this time no recrudescence of tumor growth did appear. 
However, considering the additional treatment with an ICI, atezolizumab once more 
could not improve anti-tumor effects in uninfected or MeV-GFP-infected HT29 CRC 
cells under coculture with NK cells. 
Nivolumab together with NK cell coincubation (E : T ratio 2.5 : 1) of uninfected HT29 
tumor cells did not show a consistent, sustained increase of tumor cell killing compared 
to NK cells only, which also applied for measles-infected HT29 tumor cells (see Fig. 
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23, E). Yet, a tendency of additional therapeutic gain through nivolumab application 
could be described in both MOCK- and MeV-GFP-infected HT29 tumor cells under NK 
cell cocultivation. 
As already found out for the higher E : T ratio, NK cell coincubation at an E : T ratio of 
1 : 1 achieved an early tumor cell proliferation reduction until 80 hours after start of 
measurement, followed by a second phase of tumor cell proliferation increase, so that 
the NK cell curve finally met the end point of the MeV-GFP curve (see Fig. 23, F). 
This time, addition of ICI, here atezolizumab, could attain a trend of tumor cell mass 
reduction in comparison to NK cells only, both in uninfected and MeV-GFP-infected 
HT29 tumor cells. Hence, the combination therapy of NK cells, measles virotherapeutic 
and anti-PD-L1 antibody was observed to reach best therapeutic results in this 
experiment. Still, the therapeutic effects could not accomplish those of using the higher 
E : T ratio of 2.5 : 1 in combination with ICI and measles OV. 
The last experimental setting with HT29 tumor cells tested the combination of NK cells 
at the lower E : T ratio of 1 : 1, MeV-GFP and nivolumab (see Fig. 23, G). ICI addition 
could again achieve a trend of improved tumor cell killing in the context of a triple 
therapy. Results were approximately comparable with the therapeutic effects of the 
same combination, only with atezolizumab instead of nivolumab. However, this trend 
could not be observed in uninfected tumor cells, where nivolumab together with NK 
cells acted even worse than NK cells only, thus achieving a lower therapeutic effect 
than MeV in monotherapy. 
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A) HCT-15 (2.500 cells / well), infected with MeV-GFP (MOI 10) or MOCK-infected, 
together with ICI atezolizumab and PBMC (E : T = 10 : 1) 
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B) HCT-15 (2.500 cells / well), infected with MeV-GFP (MOI 10) or MOCK-infected, 
together with ICI nivolumab and PBMC (E : T = 10 : 1) 
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C) HCT-15 (2.500 cells / well), infected with MeV-GFP (MOI 10) or MOCK-infected, 
together with ICI atezolizumab and NK cells (E : T = 1 : 1)
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D) HCT-15 (2.500 cells / well), infected with MeV-GFP (MOI 10) or MOCK-infected, 
together with ICI nivolumab and NK cells (E : T = 1 : 1) 
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E) HCT-15 (2.500 cells / well), infected with MeV-GFP (MOI 10) or MOCK-infected, 
together with ICI atezolizumab and nivolumab and NK cells (E : T = 1 : 1) 
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F) HCT-15 (2.500 cells / well), infected with MeV-GFP (MOI 10) or MOCK-infected, 
together with ICI atezolizumab and NK cells (E : T = 0.5 : 1) 
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G) HCT-15 (2.500 cells / well), infected with MeV-GFP (MOI 10) or MOCK-infected, 
together with ICI nivolumab and NK cells (E : T = 0.5 : 1) 
 
Figure 24, A - G: xCELLigence real-time cell proliferation assay of HCT-15 growth and 
viability under treatment with MeV-GFP, immune checkpoint inhibitors and PBMC / NK 
cell coculture 
xCELLigence real-time cell monitoring assay was used to investigate growth and viability of 
human CRC cells over a period of 130 hours under influence of a combination of MeV-GFP, 
treatment with ICI and PBMC or NK cell coculture. 
21 hours after plating of 2.500 HCT-15 tumor cells per well, infection with MeV-GFP at MOI 
10 or MOCK infection took place. At 51 hpi, NK cells or PBMC, which both had optionally 
been incubated with 5 μg / ml of nivolumab and / or atezolizumab one hour before, were added 
at an E : T ratio of 10 : 1 for PBMC and 1 : 1 or 0.5 : 1 for NK cells. As a control, atezolizumab 
or nivolumab were added without immune cell coincubation. PBMC and NK cells, as described 
in 2.3, had been purified from different healthy donors before and were a kind gift of AG Salih. 
The cell index (CI) is shown as a function of time. Measurement took place in triplets; means 
and SD are shown. For each tumor cell line, one representative experiment is shown. 
Niv = nivolumab, Ate = atezolizumab, MeV = MeV-GFP, NK = NK cells. 
 
The second CRC cell line tested in xCELLigence together with immune cell 
coincubation, measles virotherapeutic and ICI was HCT-15. 
PBMC at an E : T ratio of 10 : 1 achieved tumor cell killing comparable to MeV-GFP-
addition, referring to the end point of measurement (see Fig. 24, A). In this 
experimental subset, the treatment regimen of PBMC plus MeV-GFP-infection revealed 
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as the most efficient combination concerning oncolysis. Namely, after 130 hours of 
xCELLigence analysis, the analyzed CI of the double therapy amounted roughly 1/6 of 
the CI of untreated control. Yet, the maximal tumor cell killing of Triton X-100 1 % 
could not be reached by any therapeutic regimen. 
On the other hand, atezolizumab could not further strengthen tumor cell killing in 
uninfected tumor cells with the two curves for PBMC only and PBMC plus 
atezolizumab running almost identically. In MeV-GFP-infected cells, atezolizumab even 
worsened the anti-tumor effect of PBMC coincubation (also see Fig. 24, A). 
Results with PD-1-targeting nivolumab were comparable to those with atezolizumab 
(see Fig. 24, B). Best effects in tumor cell killing were achieved with the combination 
PBMC plus MeV-GFP, whereas ICI addition accomplished less tumor reduction 
(PBMC plus MeV-GFP plus nivolumab) or showed no therapeutic difference (PBMC 
plus nivolumab). 
The next step was to examine the influence of ICI addition on therapeutic effects of a 
combination of NK cells at E : T ratio 1 : 1 and MeV-GFP virotherapeutic (see Fig. 24, 
C). In this case, NK cell-induced decrease of CI was more distinct than the measles-
induced reduction. Still, the double treatment MeV plus NK cells achieved less 
therapeutic benefit in comparison to the findings in PBMC. Again, the combination NK 
cells plus MeV outplayed the two monotherapies in its therapeutic effect. 
After addition of atezolizumab, a trend of further CI reduction could be observed in 
comparison to NK cells plus MeV only; but in uninfected cells, this trend was not 
consistent. Maximum therapeutic effects, this time induced by triple therapy, again 
achieved CI reduction to about 1/6 of CI of control after 130 hours of analysis (also see 
Fig. 24, C). 
With nivolumab, observations in xCELLigence analysis were mostly the same: A trend 
of further CI reduction via PD-1-targeting ICI became only apparent in MeV-GFP-
infected HCT-15 tumor cells, but not in uninfected, where nivolumab addition induced a 
tendency of less therapeutic effect than NK cell coincubation alone (see Fig. 24, D). 
Still, the trend towards additional therapeutic use of ICI application as part of a triple 
combination therapy together with MeV and NK cells was observed slightly more 
noticeable than with atezolizumab, referring to Fig. 24 C. 
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Interestingly, application of both atezolizumab and nivolumab (see Fig. 24, E) could in 
turn not affirm a consistent trend of additional therapeutic effect in comparison to a 
regimen with NK cells plus MeV or to a treatment with NK cells only, which 
contradicted the findings of single ICI addition in Fig. 24 C and D. 
Besides, reduction of the NK cell E : T ratio from 1 : 1 to 0.5 : 1 could also not reveal 
an improved therapeutic benefit of ICI addition (see Fig. 24, F). This time, NK cells 
could not reach the amount of tumor cell killing of MeV-GFP-treatment. Nevertheless, 
the combination of NK cells plus MeV was still very successful in CI reduction, again 
reaching a CI of roughly 1/6 of the CI of untreated control after 130 hours of 
xCELLigence real-time analysis. In other words, combination therapy with MeV and 
NK cells at an E : T ratio of 0.5 : 1 could attain results in HCT-15 CRC treatment 
comparable to the same regimen with a higher E : T ratio of 1 : 1. Nonetheless, triple 
therapy with atezolizumab showed less therapeutic effect than the combination of OV 
and NK cells. 
The same lack of improved therapeutic effects was observed after addition of nivolumab 
to the combination of MeV plus NK cells (E : T = 0.5 : 1) (see Fig. 24, G). In this case, 
tendency towards less anti-tumor efficacy became even more striking than for 
atezolizumab in Fig. 24 F. 
 
To put it into a nutshell and recapitulate the findings of several xCELLigence runs, it 
could be observed in real-time cell viability and proliferation analysis of HT29 as well 
as HCT-15 tumor cell lines that (i) a treatment with MeV-GFP or immune cells 
considerably decreased CIs of both tumor cell lines and that (ii) a combined treatment 
of MeV-GFP infection and immune cell coincubation even resulted in additional 
reduction of CIs; but on the other hand, (iii) a combination of ICI (nivolumab and / or 
atezolizumab) in a triple therapeutic regimen together with measles virotherapeutic and 
immune cells could not further reduce tumor cell mass and viability in a consistent or 
sustainable way. 
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3.5. Quantification of antiviral effects of immune checkpoint inhibitors on the 
replication of MeV-GFP in human colorectal carcinoma cell lines 
The therapeutic principle behind immune checkpoint blockade with nivolumab or 
atezolizumab is the inhibition of PD-1 / PD-L1 interaction, which physiologically 
initiates a downregulation of anti-tumor immunity. But on the other hand, such an ICI-
induced stimulation of the human immune system might not only cause an efficient 
anti-tumor immune response, but also lead to an activation of immunological processes 
inhibiting viral spread and replication. 
Necessarily, this aspect has also to be taken into account referring to MeV-GFP-based 
virotherapy in combination with anti-cancer immunotherapy. Thus, the influence of ICI 
on MeV-GFP replication in human CRC cell lines became focus of our investigations. 
 
3.5.1. Quantification of antiviral effects of immune checkpoint inhibitors in a viral 
growth curve model on MeV-GFP-infected HT29 and HCT-15 tumor cells 
In a first step, viral growth curves were used to analyze the effect of immune checkpoint 
blockade on MeV-GFP replication in infected human CRC cell lines. Due to limited 
access to ICI, pembrolizumab was used for viral growth curves instead of nivolumab, 
both targeting the immune checkpoint receptor PD-1. The MOIs used for measles-
infection were selected accordingly to the different resistance patterns towards MeV-
induced oncolysis, which had been investigated with SRB assays before (see 3.1.1). 
The two tumor cell lines HT29 and HCT-15 were analyzed, which had also been used 
for xCELLigence analysis. 
A) Viral growth curves on MeV-GFP-infected HT29 (MOI 5) 
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B) Viral growth curves on MeV-GFP-infected HCT-15 (MOI 10) 
    
 
Figure 25, A - C: Quantification of antiviral effects of immune checkpoint inhibitors in a 
viral growth curve model on HT29 and HCT-15 tumor cells 
For viral growth curves, supernatants as well as lysates of human CRC cells, which had been 
infected with MeV-GFP at MOIs of 5 or 10 before, were collected at 3, 24, 48, 72 and 96 hpi. 
ICIs pembrolizumab or atezolizumab (10 µg / ml) were added directly after infection. Titration 
was done on Vero cells. 
 
First, kinetics of viral replication and virus release were examined in human colorectal 
cancer cells without further ICI treatment. Both colorectal tumor cell lines achieved a 
maximum of MeV-GFP-production and -release at 48 hpi. Amounts of virus detected in 
tumor cell lysates were approximately comparable to those in supernatants, referring to 
the samples taken at 3, 24, 48, 72 and 96 hpi. The decrease of titers at 72 and 96 hpi 
could be explained by reduction of tumor cell mass through oncolysis, hence equating 
to a diminished capacity of virus production machinery. 
Virus titers reached 105 PFU / ml after infection at a MOI of 10 for HCT-15 and 
between 105 and 106 PFU / ml after infection at a MOI of 5 for HT29. These results 
could be expected, considering the different characteristics of resistance against MeV-
induced oncolysis. Moreover, the findings were approximately comparable to results of 
viral growth curves of MeV-SCD in HCT-15, conducted in our working group by Noll 
et al. (Noll M., 2013). 
Excluding the influence of NK cells or PBMC in this viral growth curve model, neither 
pembrolizumab nor atezolizumab influenced titers of MeV-GFP in supernatants or 
lysates of both tumor cell lines. These findings could exclude a direct influence of ICI 
on MeV-GFP replication kinetics or spread in the tested CRC cell lines. 
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3.5.2. Quantification of antiviral effects of immune checkpoint inhibitors in MeV-
GFP-infected HT29 and HCT-15 tumor cells after immune cell cocultivation 
In a next step, the influence of immune cell cocultivation was taken into account for 
analysis of the effects of ICI on viral replication and spread, so that the possibility of 
PD-1 / PD-L1 interaction between tumor cells and immune cells was given. 
After MeV-GFP-infection of human CRC cells, viral titers were compared under 
different treatment conditions, including addition of ICI nivolumab and / or 
atezolizumab. For immune cell cocultivation, NK cells were used with an E : T ratio of 
2.5 : 1; PBMC were applied with an E : T ratio of 10 : 1. 
The two tumor cell lines HT29 and HCT-15 were analyzed, which had also been used 
for xCELLigence analysis. 
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HCT-15 
    
    
Figure 26: Quantification of antiviral effects of checkpoint inhibitors via virus titration on 
HT29 and HCT-15 tumor cells 
In order to quantify conceivable effects of immune checkpoint blockade on viral replication in a 
model of human CRC cell / immune cell cocultivation, viral titers of each supernatants and 
lysates were determined after infection with MeV-GFP (MOI 1 for HT29 or MOI 10 for HCT-
15), treatment with nivolumab or atezolizumab and cocultivation with NK cells (E : T = 2.5 : 1) 
or PBMC (E : T = 10 : 1). 
Six treatment groups were differentiated: MeV-GFP-infected cells (i) without further treatment, 
(ii) with PBMC cocultivation alone, with PBMC cocultivation and additional (iii) nivolumab or 
(iv) atezolizumab incubation, with (v) PBMC cocultivation together with combined application 
of both nivolumab and atezolizumab or (vi) with PBMC cocultivation and IgG control. For ICI 
or human IgG control incubation, concentrations of each 5 µg / ml were used. 
Supernatants as well as lysates of the different treatment regimes were collected at 48 hours 
after cocultivation with immune cells. Titration was done on Vero cells. 
One out of two independent experiments is shown each. 
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viral replication in comparison to controls without ICI treatment or to controls with 
human IgG treatment instead. This seemed to be consistent with results observed in 
viral growth curve models on HT29 CRC cells (Fig. 25, A). Addition of immune cells 
alone did not reduce viral titers by more than a factor of 10. Application of IgG control 
together with NK cells / PBMC resulted in viral titers comparable to those after immune 
cell coculture. 
In a second experiment of NK cell / PBMC cocultivation, this time with MeV-GFP-
infected HCT-15 tumor cells, viral titers were again impaired by immune cell coculture, 
ranging between a factor of 100 to 1.000. As HCT-15 cells had proven to be MeV-GFP-
resistant in cytotoxicity assays (Fig. 14), supernatants as well as lysates generally 
contained a lower amount of viral particles than HT29, thus resulting in lower viral 
titers on average. Furthermore, it should be taken into account that a difference in 
immune cell-induced reduction of virus proliferation between the two CRC cell lines 
could also be due to various extents of MHC mismatch effects, relating to separate 
donors of immune cells and the different NCI-60 human tumor cell lines. 
Apart from that, treatment with nivolumab and / or atezolizumab showed no interference 
with viral replication in HCT-15 tumor cells as well. Referring to NK cells, no 
homogeneous reduction of viral titers by adding ICI could be observed in supernatants 
or lysates. Only in comparison to human IgG control, atezolizumab achieved a titer 
reduction of about factor 10 in supernatants. Referring to PBMC, ICI-induced decrease 
of viral titers of more than factor 10 could be observed neither in supernatants nor in 
lysates. These findings also seemed to be consistent with the results of viral growth 
curves on HCT-15 tumor cells (Fig. 25 B). 
 
In conclusion, ICI alone without immune cell coculture did not have any influence on 
replication in a viral growth curve model. Moreover, viral titrations under PBMC or NK 
cell coculture could not show a consistent influence of ICI on viral spread either. 
This correlated with the observations in in vitro xCELLigence real-time tumor cell 
growth and viability analysis, where ICI were found to have no additional anti-tumor 
effects in comparison to measles virotherapeutic and immune cells only. 
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4. Discussion 
 
The history of virotherapy can be dated back to the discovery of viruses over 100 years 
ago. In this context, the presumption that both naturally acquired viral infections and 
vaccinations with attenuated virus strains could induce regression of malignant tumors 
was reinforced by numerous clinical case reports (Bierman et al., 1953; Bluming, 1971; 
Hansen and Libnoch, 1978). The height of virotherapy was heralded with the possibility 
of genetic engineering of the viral genome, thus further improving tumor specificity 
(Hammond et al., 2001; Bucheit et al., 2003), implementing a non-invasive 
reconstruction of viral replication kinetics in the human organism (Peng et al., 2002a; 
Dingli et al., 2004) or realizing a supplemental activation of the host immune system 
against mutated tumor cells (Grossardt et al., 2013). 
With the genetically modified herpes simplex virus Talimogene laherparepvec 
(Imlygic®, Amgen), a first virotherapeutic was FDA- as well as EMA-approved for 
treatment of advanced melanoma in 2015 (Andtbacka, 2015; FDA, 2015). Beyond, 
MeV also became subject of clinical case reports and early clinical trials in cancer 
patients (Msaouel et al., 2009; Russell et al., 2014; Robinson and Galanis, 2017). But 
nonetheless, virotherapy still implicates serious obstacles for research, as monotherapy 
with OVs already encountered in vitro resistances in several tumor entities, including 
human CRC cell lines (Noll M., 2013), hence making new multimodal treatment 
strategies inevitable. 
A combined therapeutic regimen with ICI, for example mAbs against PD-1 and PD-L1, 
was chosen to overcome preexisting resistances by strengthening and consolidating the 
oncolysis-induced anti-tumor immune response (Dias JD, 2012; Engeland CE, 2014; 
Quetglas JI, 2015; Rojas et al., 2015; Woller N, 2015; Cockle et al., 2016; Rajani K, 
2016; Shen et al., 2016). In terms of partly ineffective monotherapeutic treatment of 
CRC with ICI (Jager et al., 2016), this multimodal approach seems particularly 
interesting to uncover the power of immunotherapy. 
In view of high prevalence and, on the other hand, still poor OS rates for metastatic 
disease in CRC (Gustavsson et al., 2015), our focus was set on three human CRC cell 
lines: HT29, HCT-15 and SW-620. 
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In vitro mono-treatment of human CRC with MeV virotherapeutic or ICI was not 
efficient enough to fully eradicate all tumor cell lines, partly facing preexisting 
resistances. 
In a first phase, monotherapeutic approaches for treatment of CRC were tested for their 
cytotoxic potential via Sulforhodamine B viability assay. 
For the measles virotherapeutic MeV-GFP, different patterns of resistance were found 
for the three human CRC cell lines. In detail, HT29 were found to be susceptible 
towards MeV-induced oncolysis, whereas SW-620 and HCT-15 showed preexisting 
resistance at 72 and 96 hpi, displaying remaining cell masses of almost 100 % at MOI 1. 
For SW-620, this resistance could be overcome by raising the MOI to 5 and 10. In 
contrast, not even an increase of the MOI up to 10 was able to overcome the resistance 
in HCT-15 tumor cells. These results complement findings of our laboratory, described 
by Noll et al. (Noll M., 2013), where SRB analysis was done for our suicide-gene 
enhanced virotherapeutic MeV-SCD at 96 hpi, using a MOI of 1. Here, HCT-15 
belonged to those NCI-60 tumor cell lines revealing the highest grade of resistance 
towards MeV-SCD-induced oncolysis. Noll and colleagues considered differences in 
antiviral interferon (IFN) response to depict a possible explanation for variations in 
MeV-resistance, referring to the innate immunity of tumor cells. Thereby, expression of 
a protein called IFIT (interferon-induced protein with tetratricopeptide repeats) could be 
demonstrated in the MeV-GFP- and MeV-SCD-resistant HCT-15 tumor cells, thus 
indicating an active IFN pathway (Noll M., 2013). By the way, a residual activity of 
IFN signaling in tumor cells does not dissent with the principle of tumor-specific 
oncolysis via IFN pathway deficiency, as explained in 1.2.1: Some tumor cells may still 
dispose of a remaining innate immunity, but mostly decreased in comparison to healthy 
tissue (Haralambieva et al., 2007). 
Appraising SRB results, MeV virotherapeutic as mono-treatment was found to be not 
able to eradicate all three human CRC cell lines, hence highlighting the urgency to 
enable multimodal virotherapeutic approaches. 
In a next step, SRB cytotoxicity assays proved that nivolumab and atezolizumab both 
did not possess any innate anti-tumor traits, which could be explained by lack of an 
immune cell / tumor cell interaction to interfere with. 
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Expression of the immune checkpoint ligand PD-L1, representing a predictive as well 
as prognostic factor for ICI therapy, could be increased by MeV-infection in all three 
human CRC cell lines. 
We set a focus on the question whether infection with an oncolytic measles virus could 
have impact on expression rates of the immune checkpoint ligand PD-L1 in the different 
human colorectal tumor cells. 
First of all, basal PD-L1 expression on the different tumor cell lines was examined and 
compared with regard to different culturing conditions concerning used media and time 
of culturing. 
Expectedly, the three human CRC cell lines differed in their basal PD-L1 expression: 
HT29 appeared to be the cell line with the highest percentage of PD-L1 expressing 
cells, namely 14.8 %, followed by HCT-15 with 2.8 % and SW-620 with 2.6 %. These 
observations fit into the pattern of earlier experiments from Llosa et al., where basal 
PD-L1 expression on human CRC was examined in relation to MSI status (Llosa et al., 
2015). Interestingly, HCT-15, which belongs to the MSI fraction of CRC (Abaan et al., 
2013; Ahmed et al., 2013), was a tumor cell line with low basal PD-L1 expression rates. 
In comparison to that, HT29 with MSS status (Abaan et al., 2013; Ahmed et al., 2013) 
expressed higher rates of PD-L1. This counteracts the hypothesis that the expression of 
immune checkpoint ligands in highly immunogenic MSI cancer, based on the high 
mutational load, represents an important immune escape mechanism. But actually, 
Llosa and colleagues could also not find high rates of PD-L1 expression on CRC tumor 
cells with MSI status in immunohistochemistry. In fact, PD-L1 expression was found on 
myeloid cells as well as TILs in tumor nests, tumor stroma and the lamina propria 
invasion front (Llosa et al., 2015), creating an immunosuppressive microenvironment. 
In regard to these findings, an interesting question, which could be followed in an 
appropriate mouse model of CRC, would be how tumor-infiltrating immune cells react 
in their PD-L1 expression in case of infection with a MeV virotherapeutic. To anticipate 
this idea, Woller et al. could prove that adenovirus-induced oncolysis was able to induce 
PD-L1 expression on tumor-infiltrating APCs in murine CMT64 lung tumors. 
Moreover, addition of anti-PD-1 to OV treatment further increased PD-L1 expression 
on APCs (Woller N, 2015).
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In a next step, we examined the impact of different culturing conditions on PD-L1 
expression rates. Thereby, no consistent results for all three tumor cell lines were found. 
HT29 was the only tumor cell line to undergo consistent changes in PD-L1 expression 
after incubation with Opti-MEM for both times of measurement, hence an increase in 
PD-L1 expression was observed. In contrast to that, expression rates of PD-L1 in HT29 
CRC cells were impaired by longer duration of cultivation. This did not apply for HCT-
15 and SW-620, where PD-L1 expression rose with time of culturing. To put it into a 
nutshell, heterogeneous reactions to different culturing conditions rather negated a 
consistent mechanism of influence on PD-L1 expression, but might depict a possible 
impact of various factors of cell metabolism on PD-L1 expression. 
Finally, tumor cells were infected with the virotherapeutics MeV-GFP and MeV-SCD 
to analyze the consequences of MeV-OV treatment on PD-L1 expression, and thus on a 
possible ICI application. FACS analysis of immune checkpoint ligand expression after 
MeV-SCD-infection was performed to avoid distracting interference of the GFP with 
isotype- and anti-PD-L1-PE staining, arising especially in MeV-GFP-susceptible HT29 
tumor cells. In favor of a multimodal immunovirotherapeutic approach, measles 
infection induced a sustainable increase of PD-L1 expression in all three human CRC 
cell lines. Even in high-grade MeV-resistant HCT-15 tumor cells, MeV-SCD infection 
could increase PD-L1 expression from an original extent of 5.9 % for MOCK infected 
cells at 24 hpi to 35.6 % for infected cells at 48 hpi, using a MOI of 10. Moreover, PD-
L1 upregulation through MeV-SCD-infection was found to be time- as well as MOI-
dependent for the two CRC cell lines HCT-15 and HT29. 
In contrast to these findings, PD-L1 expression in SW-620 cells correlated positively 
with MOI but not with time of culturing after MeV-SCD-infection, as expression rates 
were considerably impaired at 48 hpi in comparison to 24 hpi for MOCK, MOI 5 and 
MOI 10. However, this effect could not be reproduced by using MeV-GFP for OV-
infection or by comparing different culturing media. Perhaps advanced MeV-SCD-
induced tumor cell killing at 48 hpi led to reduction of OV-infected, PD-L1-expressing 
SW-620 cells, but this theory would not explain a difference of 26.4 percentage points 
between PD-L1 expression in MOCK infected SW-620 cells at 24 hpi vs. 48 hpi. 
As it is commonly suggested that high PD-L1 expression rates on tumor targets 
correlate with a successful outcome for ICI treatment (Topalian et al., 2012; Taube et 
Discussion 
 
114 
al., 2014; Dunne et al., 2016), it seems to be worthy to take a step forward to investigate 
therapeutic effects of ICI combined with MeV virotherapeutic in a murine CRC model. 
To give an example, combination treatment with the virotherapeutic MeV-EGFR 
(targeting epidermal growth factor receptor for host cell entry) and anti-PD-1 mAb 
could achieve prolonged survival in a syngeneic murine glioblastoma (GBM) model 
(Hardcastle et al., 2016). Moreover, Hardcastle and colleagues investigated the 
influence of MeV-NIS-infection of human GBM39 and GBM12 tumor cells on the 
expression of PD-L1. Furthermore, the impact of MeV-NIS-infection was compared 
with IFN-γ treatment. Untreated, the two human GBM cell lines barely expressed PD-
L1 after 24 hours, but IFN-γ could achieve a significant increase in PD-L1 expression 
on both cell lines, in contrast to MeV-NIS. After 36 hours, MeV-NIS was also able to 
induce a significant increase of PD-L1 expression, compared to untreated cells or to 
controls treated with UV-inactivated MeV-NIS. Interestingly, the percentage of PD-L1 
expressing GBM tumor cells 36 hours after IFN-γ treatment was again higher than after 
OV-infection (Hardcastle et al., 2016). These findings of Hardcastle et al. in an in vitro 
model of human GBM were consistent to our investigations in PD-L1 expression on 
human CRC cell lines, and could maintain the hypothesis that oncolysis through MeV 
virotherapy induces an immunological stimulus, which can be consolidated in a second 
step by antibodies targeted to PD-1 or PD-L1. The ICI-favorable tumor micro-
environment due to the PD-L1 upregulation by MeV virotherapeutic strongly endorsed 
our approach to combine MeV-GFP with ICI for treatment of human CRC. 
The important role of IFN-γ in upregulation of PD-L1 expression on tumor cells was 
also shown by Dong et al. (Dong H., 2002). It is hypothesized that tumor infiltrating 
CD8+ T-cells are activated by contact to tumor specific antigens, thus secreting IFN-γ, 
which in turn upregulates PD-L1 expression on TILs and tumor cells, leading to an 
equilibrium of controlling anti-tumor immune response (Kim and Chen, 2016). On the 
other hand, activation of immune checkpoint receptor PD-1 diminishes the induction of 
IFN-γ secretion (Keir et al., 2008). Moreover, PD-L1 upregulation on monocytes is 
described as a consequence of IFN-γ and IFN-β signaling, referring to an approach of 
restraining autoreactive processes in the context of multiple sclerosis via interferon 
(Schreiner et al., 2004). In the special case of multimodal immunovirotherapy, virus-
induced oncolysis would activate CD8+ T-cells, which produce IFN-γ, leading to an 
Discussion 
115 
ICI-favorable PD-L1 upregulation (Rajani and Vile, 2015). Finally, to support this 
hypothesis, type I IFN receptor knockout mice with B16-F10 melanoma tumors were 
found to be resistant to a combination therapy out of Newcastle disease virus (NDV) 
and CTLA-4 blockade, whereas the combination treatment in C57Bl/6 mice could 
induce long-term survival (Zamarin D, 2014). 
In contrast to our findings and to those of Hardcastle et al., Rajani et al. appraised that 
reovirus infection of murine B16 melanoma cells at a MOI of 0.1 did not lead to a PD-
L1 upregulation in FACS analysis at 4 dpi. Interestingly, in further analysis of PD-L1 
expression on B16 tumor cells after additional coincubation with NK cells from tumor 
naïve mice, reovirus infection could slightly increase PD-L1 expression in comparison 
to B16 cells only treated with NK cell coincubation (Rajani K, 2016). Considering 
prolonged survival through combination therapy of B16 melanoma with reovirus and 
anti-PD-1 in C57Bl/6 mice, Rajani et al. concluded that in vivo therapeutic effects were 
not moderated by direct influence of reovirus-infection on PD-L1 expression. Rather, an 
indirect way via increased NK cell activation against reovirus-infected B16 tumor cells 
was discussed. 
On the one hand, differences between varying OVs and between in vitro mice and 
human tumor models should be taken into account. On the other hand, successful 
implementation of an OV / ICI combination therapy in a B16 melanoma mouse model, 
despite the background of lacking reovirus-induced PD-L1 upregulation (Rajani K, 
2016), points out that our multimodal immunovirotherapeutic approach should be 
transferred to a suitable immunocompetent CRC mouse model, even now that MeV 
infection seems to pave the way for successful ICI application. 
Taking the latest findings into account, first clinical trials support the hypothesis of 
improved efficacy in combining OVs with ICI: Talimogene laherparepvec and 
pembrolizumab were tested in patients with advanced melanoma, resulting in an ORR 
of 62 % and an acceptable toxicity profile in comparison to the respective 
monotherapies (NCT02263508) (Ribas et al., 2017). Remarkably, by adding the OV to 
the PD-1 inhibitor, therapeutic response was found to become independent from 
individual baseline levels of PD-L1 and IFN-γ expression or CD8+ T-cell infiltration. 
These results, even though referring to a phase I clinical trial with limited patient 
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numbers and a focus on safety, strongly underline our hypothesis of viral oncolysis 
overcoming preexisting resistances against immune checkpoint blockade. 
 
Poor PD-1 expression on NK cell populations from four different healthy donors 
could impair preconditions for achieving in vitro therapeutic effects with ICI 
treatment. 
In a next step, we examined whether CD56 positive NK cell subsets from healthy 
donors could express the immune checkpoint receptor PD-1, inevitable as a target for 
immune checkpoint blockade. The focus was set on NK cell populations, as they 
represent a part of the early, innate anti-cancer immune response (Waldhauer and 
Steinle, 2008), reproduced in the rather short measurement period of subsequent 
xCELLigence experiments. 
Our FACS analysis showed that the CD56 positive NK cells did not express PD-1 in a 
sustainable way: Neither in PBMC cultures (donor #1 and #2), nor in expanded NK 
cells (donor #3 and #4), more than 0.8 % of cells expressed PD-1, referring to CD56 
positive cell populations. Interestingly, there was a PD-1 positive, CD56 negative cell 
subset among expanded NK cells, namely 1.9 % of cells from donor #3 and 2.8 % of 
cells from donor #4. 
The result that almost no PD-1 expression could be found on CD56 positive NK cells 
seems to coincide with the experiments of Pesce et al. Here, PD-1 expression was 
investigated with the finding that NK cells of only about one fourth of overall 200 
healthy donors were able to express PD-1 in high levels. Furthermore, this PD-1 
positive population of NK cells was described as a CD56dim NK cell subset (Pesce et al., 
2016), referring to a differentiation between CD56dim CD16bright NK cells, which make 
up about 90 % of the human NK cells and hold a cytotoxic function, and CD56bright 
CD16dim NK cells, which were found to play an immunoregulatory role (Cooper et al., 
2001). 
Referring to investigations of a reovirus / ICI combination therapy from Rajani and 
colleagues in an in vitro model of murine B16 melanoma, the NK cells used for 
cocultivation, which had been purified from spleen or lymph nodes of tumor naïve 
C57Bl/6 mice beforehand, barely expressed PD-1. Hence, it was suggested that the 
process of ICI-induced NK cell activation did not happen in the direct way of blocking 
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PD-1 receptors located on NK cells, but via cytokine production by PD-1 positive 
mediator cells, which were found in the NK cell-enriched cultures, and which were 
further described as CD3 positive (Rajani K, 2016). 
To reconsider our findings, the low PD-1 expression rates on the tested NK cell sub-
populations could provide a possible explanation for the lack of additional therapeutic 
effects of ICI treatment in xCELLigence analysis. 
 
xCELLigence real-time tumor cell growth and viability analysis revealed outstanding 
therapeutic effects for a combination of MeV virotherapeutic and immune cell 
coincubation, but no additional tumor cell killing through ICI addition. 
For in vitro investigation of our immunovirotherapeutic approach in CRC, 
xCELLigence analysis of tumor cell proliferation and viability was chosen with the 
advantage of real-time measurement over a period of 130 hours. Notwithstanding, this 
in vitro model of tumor cell / immune cell coculturing could only depict a very 
simplified model of the complex human immune system, including limited possibilities 
concerning duration of measurement. 
In a first step, it was examined whether the addition of ICI alone could achieve 
therapeutic effects in uninfected as well as MeV-GFP-infected CRC cells without the 
influence of immune cell coculture. As expected, MeV alone already led to considerable 
tumor cell killing in HT29 cells. But neither atezolizumab nor nivolumab could 
sustainably diminish tumor cell growth and viability in comparison to controls, albeit 
surprisingly, a slight trend towards an increased tumor cell killing could be appraised in 
case of ICI addition to both infected and uninfected HT29 cells. Referring to HCT-15 
tumor cells, treatment with MeV-GFP at the high MOI of 10 could considerably reduce 
tumor cell mass, although this cell line was found to be resistant to a great extent 
towards MeV-induced oncolysis in end point SRB assays. Maybe, this effect could be 
partly traced back to the extremely low CRC cell counts seeded on xCELLigence E-
plates. Moreover, ICI addition led to a trend of decrease of CIs in uninfected, but not in 
infected HCT-15 tumor cells. Hence again, no consistent ICI-induced impairment of 
tumor cell growth and viability could be observed without a possible immune cell 
interaction. 
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To take a step forward, we hereupon cocultured CRC cells with NK cells or PBMC, 
respectively, and repeated the additional MeV-GFP-infection. Monotreatment with 
immune cells also attained good results in tumor cell killing compared to single MeV-
infection, comprehensibly dependent on E : T ratios and further uncontrollable 
influencing factors, such as degree of MHC mismatch between tumor and immune cells. 
On average, immune cells plus MeV in combination achieved best therapeutic results in 
our xCELLigence setting. This phenomenon supported the hypothesis of MeV-induced 
oncolysis setting an immunogenic stimulus, thus enhancing tumor cell killing by NK 
cells or PBMC.  
Donnelly et al. could prove this phenomenon for the human melanoma cell line Mel888, 
where MeV-infection lead to an increase of CD107 expression on CD3- CD56+ NK 
cells, with CD107 being a marker for NK cell activation and degranulation (Alter, 2004; 
Donnelly et al., 2013). Additionally to the described activation of innate immunity by 
MeV-induced oncolysis, Donnelly and colleagues could also find a DC-mediated 
activation of PBMC against Mel888 tumor cells, displaying mechanisms of an adaptive 
anti-tumor immune response induced by the OV. Summing up, these findings perfectly 
correlated with the increased killing of CRC cells in our xCELLigence analysis, when 
cells were MeV-infected and cocultured with immune cells. Nonetheless, it should be 
considered that effects of an adaptive immune response, as Donnelly et al. could show 
after one and two weeks of coculture, were rather questionable in our experimental 
setting, referring to a much shorter time of coculture. 
In a next step, the influence of immune checkpoint blockade in a triple therapeutic 
regimen together with MeV-GFP and immune cells was tested. Summing up results of 
overall xCELLigence runs with HT29 and HCT-15 cells, unfortunately, neither 
atezolizumab nor nivolumab application could homogeneously lead to an additional 
therapeutic gain. When addressing this lack of desirable ICI-induced improvement of 
tumor cell killing, several aspects should be considered. 
Firstly, a preexisting anti-tumor immunity, represented by tumor-infiltrating lympho-
cytes such as CD8+ T-cells, and the thereby induced PD-L1 upregulation, functioning as 
an immune escape answer of the tumor, were found to build the basement of a 
successful ICI interaction (Herbst et al., 2014; Tumeh et al., 2014). In case of our in 
vitro xCELLigence model, no preexisting tumor immunity could be expected, as the 
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immune cells had been isolated from healthy donors, and as no coincubation with CRC 
cells had taken place prior to xCELLigence analysis. Moreover, the already mentioned 
limited period of measurement, and therefore also of coculture, could implicate a lack of 
proper interaction between tumor cells, immune cells and immune checkpoint blockade. 
Adding another point, the FACS analysis of PD-1 expression on CD56 positive NK cell 
populations revealed rather low expression rates as a precondition to take place in a PD-
1 / PD-L1 interaction, which could be inhibited by ICI. According to those findings, 
PD-1 expression rates irrespective of CD56 status were not higher than 3.5 % of overall 
cells in enriched NK cell cultures, and not higher than 15.1 % of PBMC cultures. 
Interestingly, a further mechanism of NK cell-induced tumor cell killing could include 
antibody-dependent cellular cytotoxicity (ADCC), which is mediated by interaction 
between an IgG1 mAb, such as atezolizumab, and CD16, which displays a Fc receptor 
on NK cells (Cooper et al., 2001; Veluchamy et al., 2016). In contrast to nivolumab, 
namely an IgG4 mAb, CRC cell-opsonizing atezolizumab could therefore activate 
ADCC as an anti-tumor machinery independent from PD-1 / PD-L1 interaction. 
However, no consistent therapeutic difference could be found between treatment with 
NK cells plus atezolizumab and NK cells plus nivolumab in xCELLigence analysis. 
In contrast to the lack of an additional therapeutic effect of our triple therapy in vitro, 
Rajani et al. could show a significant increase in TNF-α release by tumor-naïve NK 
cells cocultured with murine B16 melanoma cells, which had been treated with a 
combination of reovirus and anti-PD-1 or anti-PD-L1 beforehand (Rajani K, 2016). 
Measurement took place in supernatants collected two days after coincubation and four 
days after reovirus infection, thus in a time period captured by our xCELLigence 
measurement. Moreover, Rajani and colleagues could prove that this multimodal 
immunovirotherapeutic treatment of B16 cells together with NK cell coculture 
significantly decreased tumor cell mass in the case of reovirus / anti-PD-1 treatment. 
Interestingly, this measurement was executed seven days after reovirus infection, thus 
not any longer in the time period of our xCELLigence analysis. It stayed unclear 
whether an analysis of residual tumor cells was also conducted at an earlier point of 
time together with TNF-α measurement. Apart from the fact that those experiments 
took place in a murine, and not human, in vitro model, a discrepancy between the two 
experimental settings could again be attributed to the different chronology of 
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measurement in investigations of Rajani et al. and our investigations. Hence, maybe a 
longer measurement period for xCELLigence analysis should have been chosen, which 
in turn would lead to the question whether our real-time setting could really afford 
measurement durations lasting longer than a week. 
To give a résumé over testing of an immunovirotherapeutic approach beyond in vitro 
tumor cell models, many favorable results could be depicted in animal models (Gao Y, 
2009; Dias JD, 2012; Engeland CE, 2014; Zamarin D, 2014; Quetglas JI, 2015; Rojas et 
al., 2015; Woller N, 2015; Cockle et al., 2016; Hardcastle et al., 2016; Shen et al., 2016) 
and in patients (NCT01740297 (Puzanov et al., 2016), NCT02263508, NCT03069378, 
NCT02626000, NCT02965716). Referring to patients with advanced melanoma, the 
immunovirotherapeutic combination of Talimogene laherparepvec and pembrolizumab 
was lately tested in a phase 1b clinical trial by Ribas and colleagues (NCT02263508), 
whereby the OV prepared the ground for improved efficacy of the ICI, resulting in a 62 
% ORR (Ribas et al., 2017). The difficulties to display such a complex context of 
interaction between tumor, immune system, virus and ICI in vitro and the prospects of 
success with those previous preclinical and clinical trials in vivo propose further 
analysis of our multimodal therapy in an appropriate immunocompetent CRC mouse 
model. 
 
As a result for in vitro analysis of conceivable ICI-induced antiviral immune effects, 
we appraised a lack of influence on viral replication and spread. 
One major challenge in the field of immunovirotherapy emerges to be the timing of 
virus and ICI application (Rajani and Vile, 2015; Rojas et al., 2015; Marchini et al., 
2016). By exploiting the ICI-consolidated anti-tumor immune response, a likewise 
induced antiviral immune response belongs to the other side of the coin. This, on the 
one hand, could impair viral replication and spread, leading to faster clearance of the 
OV, and thus diminishing the effects of direct tumor oncolysis. On the other hand, such 
an immune response directed towards foreign viral antigens could also improve virus-
induced tumor cell killing, if the host tumor cell expressed those viral proteins on its 
surface. 
Albeit in a different context, both sides of the coin should be illuminated in discussing 
antiviral immune responses: Facing the different aspects of already preexisting antiviral 
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antibodies, which neutralize the virotherapeutic in case of systemic delivery, several 
approaches were considered to circumvent an immunological clearance of OV (see 
1.2.1). But interestingly, the - at first glance undesirable - preexisting antiviral immune 
response could not simply be equated with a reduction of OV-induced anti-tumor 
immune response, as Bridle and colleagues showed: They proved that a sustainable anti-
tumor immune response can be induced by application of oncolytic VSV together with a 
boosting anti-adenoviral vaccination beforehand, with both vaccine and oncolytic virus 
expressing specific tumor antigens (Bridle et al., 2010). 
In either case, an immunovirotherapeutic regimen requires perfect timing, which seems 
to be indispensable for orchestrating a maximum effective tumor cell killing as well as 
long-lasting anti-tumor immune response. 
As a logical next step, we tried to quantify antiviral effects of immune checkpoint 
blockade in MeV-infected human CRC cells, both in viral growth curves and in 
titrations of lysates and supernatants of tumor cells infected and cocultured with PBMC 
or NK cells. Referring to the viral growth curve model, we could not find any influence 
of ICI on viral replication and spread, as it had been expected without the possibility of 
ICI interfering with a tumor cell / immune cell interaction. In the second case of virus 
titrations under immune cell influence, an indirect mechanism of ICI impairing viral 
replication could be anticipated, namely the mechanism of ICI reducing the tumor cell 
mass and thereby the capacity of virus production. But nonetheless, virus titrations did 
also not show a homogeneous interference of ICI with viral replication in CRC cells. 
This could correlate with the lack of additional anti-tumor effects in xCELLigence 
analysis through ICI application, together with MeV and immune cell treatment. 
In contrast to our findings, Rajani et al. described an anti-PD-1 antibody-induced 
decrease of reovirus titers in murine B16 melanoma cells cocultured with tumor-naïve 
NK cells (Rajani K, 2016). This decline in viral titers went along with a significant 
reduction of tumor cell mass after treatment with reovirus, anti-PD-1 and NK cells. In 
an in vivo syngeneic model of murine renal adenocarcinoma (Renca cells) or colorectal 
adenocarcinoma (MC38), Rojas et al. could prove via bioluminescence imaging that 
addition of anti-CTLA-4 antibody significantly impaired replication of an oncolytic 
vaccinia virus expressing a luciferase transgene, when ICI was administered as early as 
0, 3 and 6 days post infection (dpi) (Rojas et al., 2015). Furthermore, Rojas and 
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colleagues investigated the effects of different time schedules for an immunoviro-
therapeutic treatment approach, resulting in the finding that in contrast to the described 
early treatment regimen, which could not show a significant tumor mass reduction, a 
second treatment regimen with ICI application at 4, 7 and 10 dpi led to a considerable 
tumor cell mass decrease and improved overall survival. To summarize, those 
investigations suggest an advantage of delayed ICI administration, leaving enough time 
for the OV to replicate and to set an immunogenic stimulus via oncolysis. 
Moreover, these considerations should be also taken into account when discussing the 
application of OVs coding for anti-PD-1 or anti-PD-L1 with the advantage of local ICI 
delivery, thereby indicating that immune checkpoint blockade takes effects shortly after 
begin of viral replication. However, in a B16-CD20 murine melanoma model, Engeland 
et al. could show that intratumorous treatment with MeV on four consecutive days, 
combined with intraperitoneal injections of anti-PD-L1 antibody at 6, 9, 12 and 15 days 
after tumor implantation, was comparable to treatment with MeV encoding anti-PD-L1, 
referring to overall survival (Engeland CE, 2014). Interestingly, the same did not apply 
for anti-CTLA-4, where systemic application in combination with MeV virotherapeutic 
led to improved survival in comparison to MeV expressing anti-CTLA-4. Again, an 
attempt to explain these differences relates to aspects of timing: CTLA-4 is described to 
play an important role in early implementation of anti-tumor immunity, in contrast to 
PD-L1, showing effects in later stages of activation of the immune system against 
malignant cells (Pardoll, 2012; Engeland CE, 2014). Therefore, systemic application of 
anti-CTLA-4 could display an advantage at the early time of maximum effect in 
comparison to probably slower delivery of locally MeV-produced ICI, so Engeland and 
colleagues. Apart from that, it would display an interesting question whether the usage 
of anti-CTLA-4 antibodies such as ipilimumab would have been beneficial for our 
xCELLigence in vitro testing with a limited time of measurement, as they implement 
early interference with the anti-tumor immune response. 
Giving a résumé of the overall investigations of ICI-induced antiviral effects, our 
findings were not in accordance with those described in literature for other tumor 
models. Considering the individual experimental settings, differences between tumor 
models, various OVs, time of application and local or systemic administration of ICI 
should not be neglected. Still, the results of virus titrations in a CRC cell / immune cell 
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cocultivation model under ICI influence were rather unexpected, probably 
correspondingly to the missing anti-tumor effects of ICI in xCELLigence. 
 
A multimodal immunovirotherapeutic approach of MeV and immune checkpoint 
blockade emerged to be worthy further testing in an immunocompetent CRC mouse 
model. 
A successful immunovirotherapeutic treatment of CRC has to be evolved from an in 
vitro model, with testing in animal experiments as a second step, followed by clinical 
trials in patients. As argued above, MeV-induced PD-L1 upregulation in CRC cells 
turned out to be auspicious for such a combined treatment regimen, providing an ICI-
favorable immunological tumor microenvironment. Therefore, albeit xCELLigence 
analysis could not reveal an additional therapeutic gain of ICI application to MeV-
infected, immune cell-coincubated CRC cells in vitro, such a treatment regimen could 
be worthy to be tested in an immunocompetent mouse model. 
A major impediment of establishing an immunovirotherapeutic approach with MeV is 
displayed by the measles tropism to human cells, which requires CD46 as a surface 
protein for measles infection of the host cell (Naniche et al., 1993). Moreover, a human 
tumor model expressing CD46 could only be adopted in immunodeficient mice, for 
example NOD / SCID (non-obese diabetic / severe combined immunodeficiency) mice. 
This again would conflict with the fact that a successful immune checkpoint blockade is 
in need of an intact immune system with all its various players, and that it cannot be 
tested in immunodeficient animals in a way that is transferable to the human organism. 
Then why not use another virus for virotherapy, which is not dependent on the human 
cell tropism? Measles vaccine virus depicts several advantages in comparison to other 
OVs developed over the last years. First of all, measles vaccine virus was proved to be 
safe in clinical usage (Buijs et al., 2015) with long-time experience in terms of 
vaccination. Secondly, successful attempts to cure patients consolidated the application 
of measles OV as anti-cancer therapeutic (Russell et al., 2014), which was further 
pursued in several clinical trials (Msaouel et al., 2009; Robinson and Galanis, 2017). 
Last but not least, investigations in our working group concerning MeV virotherapy 
could show enhancement of therapeutic efficacy by arming the OV with suicide genes 
such as SCD, transforming the harmless prodrug 5-FC into the chemotherapeutic 5-FU 
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(Graepler F., 2005; Lampe J, 2013; Lange S, 2013; Noll M., 2013; Yurttas C, 2014). To 
cut short a long story of success in measles virotherapy, it was finally worthy to redirect 
measles tropism to other targets than CD46 (Schneider et al., 2000; Bucheit et al., 2003) 
and to overcome the problems of transducing measles OV into an immunocompetent 
mouse model (Engeland CE, 2014; Hardcastle et al., 2016). Furthermore, an immuno-
competent CRC model was introduced in C57BL/6 mice, combining murine MC38 
colon adenocarcinoma cells expressing CEA with a MeV virotherapeutic, which was 
redirected to this surface marker and additionally coded for another prodrug convertase, 
purine nucleoside phosphorylase (PNP), to make oncolysis more efficient (Ungerechts 
et al., 2007). In conclusion, a logical next step would be to further evaluate our 
immunovirotherapeutic approach in such a mouse model of CRC in vivo. 
Finally, the idea of exploiting the immunogenic stimulus of measles oncolytic 
virotherapy with new immunoenhancing therapies such as immune checkpoint blockade 
will soon accomplish the phase of clinical trials, for example combining MeV with anti-
PD-1 antibody in advanced pancreatic cancer (Engeland and colleagues, not yet 
recruiting). Moreover, new immunotherapeutics such as the so-called bispecific T-cell 
engagers (BiTE) arrived in clinical usage, which are able to recognize a tumor-specific 
antigen on the one hand, and a T-cell-specific surface marker on the other hand, thereby 
merging the T-cell directly with the tumor target (Huehls et al., 2015). Combined with 
measles OV, these BiTEs are tested for consolidating a long-lasting anti-tumor T-cell 
immunity (Speck et al., 2018). 
 
To sum up our findings, which comprise a new multimodal treatment strategy for CRC 
based on a combination of MeV virotherapeutic with immune checkpoint blockade 
targeting PD-1 or PD-L1, in vitro investigations could reveal that MeV-infection clears 
the way for ICI treatment by upregulation of immune checkpoint ligand PD-L1 on CRC 
tumor cells. For the discussed reasons and for the previously presented promising 
results of further preclinical trials in the field of immunovirotherapy, the missing 
additional therapeutic effect in xCELLigence analysis of combining ICI with MeV 
virotherapeutic under immune cell cocultivation should not lead to rejection of this 
immunovirotherapeutic approach in CRC, but - quite the contrary - to further testing in 
early clinical trials, i.e. phase I/II studies. 
Summary / Zusammenfassung 
125 
5. Summary 
 
In the recent past of virotherapy, the characteristic trait of virus-induced oncolysis to 
trigger an immunogenic stimulus against malignant cells was utilized for new immuno-
virotherapeutic combination approaches, thereby overcoming preexisting resistances. 
Aim of this dissertation thesis was to investigate such a novel multimodal therapeutic 
strategy for treatment of colorectal carcinoma (CRC). In an in vitro model of human 
CRC cell lines from the NCI-60 tumor cell panel, it was tested whether immune check-
point inhibitors (ICI) could achieve a therapeutic gain, combined with an oncolytic 
measles vaccine virus expressing green fluorescent protein (MeV-GFP) and with NK 
cells or peripheral blood mononuclear cells (PBMC). 
Sulforhodamine B (SRB) cytotoxicity assays were performed to uncover preexisting 
resistances of the respective monotherapies in the different tumor cell lines. In two 
human CRC cell lines, HT29 (susceptible to measles-induced oncolysis) and SW-620 
(exhibiting an intermediate resistance to measles-induced oncolysis), infection with 
MeV-GFP achieved a multiplicity of infection (MOI)- and time-dependent reduction of 
tumor cell mass, whereas HCT-15 tumor cells were observed to be highly resistant to 
MeV-GFP-induced oncolysis. Moreover, monotherapeutic treatment of HT29 and HCT-
15 with nivolumab (targeting PD-1) or atezolizumab (targeting PD-L1) did not reduce 
tumor cell viability in the absence of immune cells. 
FACS analysis of PD-L1 expression on CRC cell lines was conducted to firstly estimate 
the basal expression of this immune checkpoint ligand, whereupon tumor cells were 
measles-infected and, in a second step, the influence of infection on PD-L1 expression 
was investigated. Showing different degrees of basal PD-L1 expression, infection with 
both MeV-GFP and MeV-SCD, a suicide gene-enhanced measles virotherapeutic 
coding for Super-cytosine deaminase (SCD), increased PD-L1 expression in all three 
human CRC cell lines. In terms of MeV-SCD-infection, expression of PD-L1 further 
rose with augmentation of MOI for all three tested CRC cell lines and also with time of 
culture after infection for two out of three tested tumor cell lines. Furthermore, 
expression rates of the immune checkpoint receptor PD-1 on CD56 positive NK cell 
populations from four different healthy donors were investigated, resulting in less than 
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1 % of PD-1 positive cells. This result can be assessed as a poor precondition to take 
place in a direct PD-1 / PD-L1 interaction. 
In a next step, we tested for augmented anti-tumor efficacy under the influence of our 
combination treatment and immune cell coculture, using the real-time tumor cell growth 
and viability xCELLigence analysis. Thereby, the combination of immune cell co-
culture with measles infection could already show increased therapeutic effects in 
comparison to the respective monotreatments, albeit unfortunately, this effect could not 
be further strengthened by additional application of ICI (nivolumab and / or atezolizu-
mab). 
Finally, antiviral effects of immune checkpoint blockade were examined: Neither in a 
viral growth curve model, nor in viral titrations after immune cell coincubation, an 
influence of ICI on replication and spread of MeV-GFP in CRC cell lines could be 
found. 
 
To summarize, the upregulation of PD-L1 on human CRC cells via MeV-infection 
correlates with a promising therapeutic setting for combining ICI with measles-based 
virotherapy. However, in vitro xCELLigence analysis under immune cell coculture 
could not reveal a therapeutic gain of our immunovirotherapeutic approach. Nonethe-
less, considering the limited possibilities of an in vitro model of the complex human 
immune system, our therapeutic regimen should be further investigated in an immuno-
competent mouse model of CRC and, even more, in the context of early clinical trials 
(i.e. phase I/II studies). 
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Zusammenfassung  
 
In der jüngsten Vergangenheit der Virotherapie wurde die spezielle Eigenschaft der 
virusinduzierten Onkolyse, einen immunogenen Stimulus gegen bösartige Zellen zu 
triggern, ausgenutzt, um mit neuen immunovirotherapeutischen Kombinationsansätzen 
vorbestehende Tumor-Resistenzen zu überwinden. 
Ziel dieser Dissertationsschrift war es, einen solchen neuen multimodalen Therapie-
ansatz für das kolorektale Karzinom (CRC) zu untersuchen. In einem in vitro Modell 
humaner kolorektaler Karzinomzelllinien aus dem NCI-60 Tumorzellverzeichnis wurde 
getestet, ob Immun-Checkpoint-Inhibitoren (ICI) einen solchen therapeutischen Zusatz-
nutzen erbringen können, wenn sie mit onkolytischen Masernimpfviren, welche grün 
fluoreszierendes Protein exprimieren (MeV-GFP), und mit NK Zellen oder peripheren 
mononukleären Blutzellen (PBMC) kombiniert werden.  
Um vorbestehende Resistenzen der jeweiligen Monotherapien in den unterschiedlichen 
Tumorzelllinien zu testen, wurden zunächst Sulforhodamine B (SRB) Zytotoxizitäts-
assays durchgeführt. In zwei humanen kolorektalen Karzinomzelllinien, HT29 (suszep-
tibel gegenüber Masern-induzierter Onkolyse) und SW-620 (intermediär resistent 
gegenüber Masern-induzierter Onkolyse), konnte eine Infektion mit MeV-GFP eine 
konzentrations- und zeitabhängige Tumorzellmassenreduktion erreichen, wohingegen 
sich HCT-15 Tumorzellen als hoch resistent gegenüber MeV-GFP-induzierter Onkolyse 
erwiesen. Außerdem konnte gezeigt werden, dass die Monotherapie von HT29 und 
HCT-15 mit Nivolumab (gerichtet gegen PD-1) oder Atezolizumab (gerichtet gegen PD-
L1) die Tumorzellviabilität in Abwesenheit von Immunzellen nicht reduziert. 
In einem weiteren Schritt wurden FACS Messungen der PD-L1 Expression auf den 
genannten Darmkrebszelllinien durchgeführt, um zunächst die basale Expression dieses 
Immuncheckpoint-Liganden zu beurteilen, woraufhin die Tumorzellen mit Masern 
infiziert wurden und in einem zweiten Schritt der Einfluss einer Infektion auf die PD-L1 
Expression untersucht wurde. Ausgehend von unterschiedlichen basalen PD-L1 
Expressionsraten konnte eine Infektion sowohl mit MeV-GFP als auch mit MeV-SCD, 
einem Suizidgen-verstärkten Masernvirotherapeutikum, das für eine Supercytosin 
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Deaminase (SCD) kodiert, die PD-L1 Expression in allen drei huamanen Darmkrebs-
zelllinien steigern. Bezüglich der Infektion mit MeV-SCD stieg die Expression in allen 
drei getesteten Darmkrebszelllinien mit der Viruskonzentration und in zwei von drei 
getesteten Tumorzelllinien auch mit der Kultivierungszeit nach der Infektion. 
Zudem wurden auch die Expressionsraten des Immuncheckpoint-Rezeptors PD-1 auf 
CD56 positiven NK Zell-Populationen von vier unterschiedlichen, gesunden Spendern 
untersucht, wobei sich weniger als 1 % PD-1 positive Zellen ergaben. Dieses Ergebnis 
kann bewertet werden als eine ausgangsmäßig schlechte Voraussetzung dafür, an einer 
direkten PD-1 / PD-L1 Interaktion teilzunehmen.  
In einer Echtzeitmessung von Tumorzellwachstum und -viabilität im xCELLigence 
Assay wurde in einem weiteren Schritt unter Einfluss von unserer Kombinations-
therapie und von Immunzellkokultur auf eine erhöhte Anti-Tumor-Effektivität getestet. 
Dabei konnte bereits durch die Kombination von Immunzellkokultur mit Masern-
infektion ein gesteigerter therapeutischer Effekt im Vergleich zu beiden Monotherapien 
gezeigt werden, der sich jedoch leider durch zusätzliche Behandlung mit ICI 
(Nivolumab und / oder Atezolizumab) nicht weiter steigern ließ. 
Schließlich wurden antivirale Effekte einer Immuncheckpointblockade untersucht: 
Weder in einem Viruswachstumskurvenmodell, noch bei Virustitrierungen nach 
Immunzellkoinkubation konnte eine Beeinflussung der Replikation und Ausbreitung 
von MeV-GFP in CRC Zelllinien durch ICI gefunden werden. 
 
Zusammenfassend kann man davon ausgehen, dass die Hochregulierung von PD-L1 auf 
humanen Darmkrebszellen durch eine Infektion mit MeV einem vielversprechenden 
therapeutischen Ansatz entspricht, um ICI und Masern-basierte Virotherapie zu kombi-
nieren. Allerdings konnten in vitro xCELLigence Analysen unter Immunzellkokultur 
zunächst keinen therapeutischen Zugewinn durch unseren immunovirotherapeutischen 
Ansatz erkennen lassen. In Anbetracht der limitierten Möglichkeiten eines in vitro 
Modells des komplexen menschlichen Immunsystems sollte unser therapeutisches 
Regime allerdings dennoch in einem immunkompetenten Darmkrebs-Mausmodell und 
besser noch im Rahmen früher klinischer Studien (Phase I/II) genauer untersucht 
werden. 
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